

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

19) JAPANESE PATENT OFFICE (JP)

12) Official Gazette for Laid-Open Patent Applications (A)

(11) Japanese Laid-Open Patent Application (Kokai) No. 8-20597

(51) Int.Cl.8      Ident. Symbols      Internal Office Nos. FI

007K    6/06

3318-4H

007D    11/28

11/56

471/12

(43) Laying-Open Date: 23 January 1996

Request for Examination: Not yet requested

Number of Claims: 3    OL    (Total of 13 pages)

(21) Application No.: 6-156006

(22) Application Date: 7 July 1994

(71) Applicant:      000006091  
Meiji Pharmaceutical Company, Ltd.  
4-16 Kyobashi 2-chome, Chuo-ku  
Tokyo-to

(72) Inventor:      Tsuneo Okonogi  
c/o General Drug Product Research Laboratories  
Meiji Pharmaceutical Company, Ltd.  
760 Morooka-cho, Kohoku-ku  
Yokohama-shi, Kanagawa-ken

(72) Inventor:      Seiji Tsutsumi  
c/o General Drug Product Research Laboratories  
Meiji Pharmaceutical Company, Ltd.  
760 Morooka-cho, Kohoku-ku  
Yokohama-shi, Kanagawa-ken

(72) Inventor:      Yoshio Akiyama  
c/o General Drug Product Research Laboratories  
Meiji Pharmaceutical Company, Ltd.  
760 Morooka-cho, Kohoku-ku  
Yokohama-shi, Kanagawa-ken

continued on last page

[continuation on page 13]

(72) Inventor:      Shokichi Ouchi  
c/o General Drug Product Research Laboratories  
Meiji Pharmaceutical Company, Ltd.  
760 Morooka-cho, Kohoku-ku  
Yokohama-shi, Kanagawa-ken

(72) Inventor:      Emiko Hatsushiba  
c/o General Drug Product Research Laboratories  
Meiji Pharmaceutical Company, Ltd.  
760 Morooka-cho, Kohoku-ku  
Yokohama-shi, Kanagawa-ken

[return to page 1]


44. [Title of the Invention] Heterocyclic Carbonyl Compounds a Thrombin Inhibiting Action

57. [Abstract]

[Objective]

[Structure] This invention relates to compounds and pharmacologically permissible salts thereof as indicated by general formula (I) below that have inhibitory activity against thrombin and that can be used in preventing and treating thrombosis.

[Chemical Formula 18]




[Wherein, A indicates a heterocyclic group, R<sup>1</sup> indicates an alkyl group, a guanidino group, an amidino group, an amidinothio group, an amino group, an hydroxyl group, a mercapto group, a lower alkoxy group or a phenyl group that may be substituted, B indicates an amino acid residue, R<sup>2</sup> indicates a methyl group, a cycloalkyl group, an aryl group, a heterocaryl group or an arylthio group, X indicates a hydrogen atom, an hydroxyl group, an amino group, a halogen atom, an alkylamino group, an acylamino group or an alkoxy-carbonylamino group, m indicates an integer of 1 to 50 and n indicates an integer of 0 to 4.]

[Claims]


[Claim 1] Heterocyclic compounds and pharmacologically permissible salts thereof as indicated by general formula (I) below.

[Chemical formula 1]



[Wherein, A indicates a monoheterocyclic ring which is a 5 member or 6 member saturated, partially saturated or unsaturated ring having at least 1 nitrogen atom or diheterocyclic ring in which benzene rings or pyridine rings are condensed (which heterocyclic rings may have oxygen atoms, iodine atoms or three or less separate nitrogen atoms, in which monoheterocyclic rings, the carbon atoms in the ring, and, in which diheterocyclic rings, the carbon atoms in the benzene ring or the pyridine ring, may be substituted by lower alkyl groups having 1 to 4 carbons atoms, halogens, hydroxyl groups, amino groups or mercapto groups, and which rings may be bonded to the carbonyl group by any of the carbon atoms that form the heterocyclic rings), R<sup>1</sup> indicates an alkyl group having 1 to 4 carbon atoms and which may be branched, a guanidino group, an amidinothio group, an amidino group, an amino group, an hydroxyl group, a mercapto group or a lower alkoxy group or a phenyl group that may be substituted by a guanidino group, an amidino group, an amino group, an hydroxyl group, a mercapto group or a halogen, B indicates a residue that can be selected from the following substances


## [Chemical Formula 2]



(wherein,  $R^1$  is an alkyl group having 1 to 6 carbon atoms and which may be branched, a phenyl group or a phenylmethyl group),  $R^2$  indicates a methyl group, an aryl group, a cycloalkyl group, a heteroaryl group, a arylthio group or a methyl group that is bonded with X, X indicates a hydrogen atom, an hydroxyl group, an amino group, a halogen atom, an alkylamino group having 1 to 4 carbon atoms, an acylamino group, an alkoxy carbonylamino group or an aryloxy carbonylamino group, m indicates an integer of 1 to 5 and n indicates an integer of 0 to 4).

[Claim 2] A heterocyclic carbonyl compound in which, in general formula (I) in Claim 1, A indicates a thiazole, an oxazole, an imidazole, a thiazoline, an oxazoline, an imidazoline, a pyridine, a pyrimidine, a pyrazole, a 1,2,4-thiadiazole, a 1,2,4-oxadiazole, a 1,2,4-triazole (which heterocyclic rings are bonded to the carbonyl group by any of the carbon atoms of which they are formed), a benzothiazole, a benzoxazole, a benzimidazole, a thiazolo[5,4-b]pyridine, a thiazolo[4,5-b]pyridine or an imidazo[4,5-b]pyridine (which heterocyclic rings are bonded to the carbonyl group by the carbon atom in the 2nd position),  $R^1$  indicates a guanidino group, an amidinothio group, an amidino group, an amidino group, an amino group, an hydroxyl group, a mercapto group or a lower alkoxy group or a phenyl group that may be substituted by a guanidino group, an amidino group, an amino group, an hydroxyl group, a mercapto group or halogens, B indicates a residue that is selected from substances of the following formulas

## [Chemical Formula 3]



wherein R<sup>1</sup> has the same significances as defined in general formula (I), R indicates a methyl group, a phenyl group that may have substituted groups, a trienyl group, a pyridyl group, an indolyl group, a naphthyl group, a diphenylmethyl group, a cyclopentyl group, a cyclohexyl group, a phenylthio group or methylene that is bonded with X, X indicates a hydrogen atom, an hydroxyl group, an amino group, a halogen atom, an alkylamino group with 1 to 4 carbon atoms, an acylamino group, an alkoxycarbonylamino group or an aryloxycarbonylamino group, m indicates an integer of 1 to 5 and n indicates an integer of 0 to 4.

[Claim 3] A thrombin inhibitor that contains the heterocyclic compounds described in Claims 1 or 2 or pharmacologically permissible salts thereof as its effective components.

[0001]

[Field of industrial use] This invention relates to novel heterocyclic carbonyl compounds that have thrombin inhibiting action.

[0002]

[Prior art] Known compounds that exhibit thrombin inhibiting activity are described, for example, in Japanese Patent Application Early Disclosure No. 54-100342 (1979) and U.S. Patents No. 4399065 and 4927809. However, these existing compounds do not have sufficient thrombin inhibiting activity. Therefore, there is a demand for compounds having higher activity and enzyme selectivity.

[Synopsis of the invention]

[0003]


[Problems the invention is intended to solve] On the basis of research on protease inhibitors, the inventors discovered a group of novel compounds that have thrombin inhibiting activity. Consequently, this invention has the objective of providing novel heterocyclic carbonyl compounds having thrombin inhibiting activity. This invention has the further objective of providing thrombin inhibitors that contain these novel heterocyclic carbonyl compounds having thrombin inhibiting action as their effective components.

[0004]

[Means for solving the problems] The heterocyclic carbonyl compounds of this invention are the compounds indicated by general formula 1 below and pharmacologically permissible salts thereof.

[0005]


[Chemical Formula 4]



[Wherein, A indicates a monoheterocyclic ring which is a 5 member or 6 member saturated, partially saturated or unsaturated ring having at least 1 nitrogen atom or diheterocyclic ring in which benzene rings or pyridine rings are condensed (which heterocyclic rings may have oxygen atoms, iodine atoms or three or less separate nitrogen atoms, in which monoheterocyclic rings, the carbon atoms in the ring, and, in which diheterocyclic rings, the carbon atoms in the benzene ring or the pyridine ring, may be substituted by lower alkyl groups having 1 to 4 carbon atoms, halogens, hydroxyl groups, amino groups or mercaptan groups, and which rings may be bonded to the carbonyl group by any

of the carbon atoms that form the heterocyclic rings), R<sup>1</sup> indicates an alkyl group having 1 to 4 carbon atoms and which may be branched, a guanidino group, an amidinothio group, an amidino group, an amino group, an hydroxyl group, a mercapto group or a lower alkoxy group or a phenyl group that may be substituted by a guanidino group, an amidino group, an amino group, an hydroxyl group, a mercapto group or a halogen, B indicates a residue that can be selected from the following substances

[Chemical Formula 5]



Wherein R<sup>1</sup> has the same significances as defined in general formula (I), R indicates a methyl group, a phenyl group that may have substituted groups, a thienyl group, a pyridyl group, an indolyl group, a naphthyl group, a diphenylmethyl group, a cyclopentyl group, a cyclohexyl group, a phenylthio group or methylene that is bonded with X, X indicates a hydrogen atom, an hydroxyl group, an amino group, a halogen atom, an alkylamino group with 1 to 4 carbon atoms, an acylamino group, an alkoxycarbonylamino group or an arylalkoxycarbonylamino group, m indicates an integer of 1 to 5 and n indicates an integer of 0 to 4.

Further, the thrombin inhibitor and anticoagulant of this invention are substances that contain the compounds of the aforementioned general formula (I) and pharmacologically permissible salts thereof. The compounds of the aforementioned general formula (I) of this invention have strong thrombin inhibiting activity and are useful as medicinal drugs.

[0007] [Specific description of the invention] The substituted group indicated by A in general formula (I) is a monoheterocyclic ring which is a 5 member or 6 member saturated, partially saturated or unsaturated ring having at least 1 nitrogen atom or diheterocyclic ring in which benzene rings or pyridine rings are condensed (which heterocyclic rings may have oxygen atoms, iodine atoms or three or less separate nitrogen atoms, in which monoheterocyclic rings, the carbon atoms in the ring, and, in which diheterocyclic rings, the carbon atoms in the benzene ring or the pyridine ring, may be substituted by lower alkyl groups having 1 to 4 carbons atoms, halogens, hydroxyl groups, amino groups or mercaptan groups, and which rings may be bonded to the carbonyl group by any of the carbon atoms that form the heterocyclic rings). Preferably, they are monoheterocyclic rings such as a thiazole, an oxazole, an imidazole, a triazole, an oxadiazole, an imidazoline, a pyridine, a pyrimidine, a pyrazole, a 1,2,4-thiadiazole, a 1,2,4-oxadiazole or a 1,2,4-triazole ring (which heterocyclic rings are bonded to the carbonyl group by any of the carbon atoms of which they are formed) or a diheterocyclic ring such as a benzothiazole, a benzoxazole, a benzimidazole, a thiazolo[5,4-b]pyridine, a thiazolo[4,5-b]pyridine or an imidazo[4,5-b]pyridine ring (which heterocyclic rings are bonded to the carbonyl group by the carbon atom in the 2nd position).


[0008] In addition, the substituted group indicated by R<sup>1</sup> in general formula (I) is a methyl group, an isopropyl group, a guanidino group, an amidino group, an amidino group, an amino group, an hydroxyl group, a mercapto group, a lower alkoxy group or a phenyl group that may be substituted by a guanine (sic) group, an amidino group, an amino group, an hydroxyl group, a mercapto group or a halogen atom and m is an integer of 1 to 5.

Preferably, R<sup>1</sup> is a guanidino group, an amidino group or an amino group or a phenyl group that is substituted by a guanidino group, an amidino group or an amino group and m is an integer of 3 to 5.

[0009] The residues indicated by B in general formula (I) are  $\alpha$ -amino acids, amino acid residues or straight chain or cyclic carbonyl compounds. Preferably, they are residues selected from compounds of the following structural formulas.

[0010]

[Chemical Formula 6]



(Wherein, R<sup>1</sup> has the same significances as defined in general formula (I).)


[0011] The substituted group indicated by R<sup>2</sup> in general formula (I) is an alkyl group that may be branched, an aryl group, a phenyl group that may be substituted, a cycloalkyl group, a heterocyclic saturated (aromatic) ring that contains 1 or 2 nitrogen atoms or a 5- or 6-member heterocyclic saturated (aromatic) ring that contains one oxygen atom or sulfur atoms, in which methylene is bonded with A and in which n is an integer of 0 to 5. Preferably, R<sup>2</sup> is a phenyl group, a diphenylmethyl group, a biphenyl group, a naphthyl group, a pyridyl group, a pyrrole group, an indolyl group, a thienyl group, a furanyl group or a phenylthio group and the heterocyclic ring that is formed by the methylene that is bonded with X is pyrrolidine or piperidine and n is an integer of 0 to 2.

[0012] The substituted groups indicated by X in general formula (I) are hydrogen, halogens, hydroxyl groups, amino groups, alkylamino groups, acylamino groups and alkoxy carbonylamino groups. Preferably, they are amino groups, methylamino groups, acetylamino groups, phenylacetylamino groups, benzyloxycarbonylamino groups and t-butoxycarbonylamino groups.

[0013] The desirable compound groups of this invention are compounds in which, in general formula (I), A is a thiazole, R<sup>1</sup> is a guanidino group, B is a residue selected from substances of the following structural formulas

{0014}


{Chemical Formula 7}



(wherein  $R^1$  has the same significance as defined for general formula (I)),  $R^2$  is an aryl group, a cycloalkyl group or a phenylthio group,  $X$  is hydrogen, an amino group or a benzyloxycarbonylamino group,  $m$  is 3 and  $n$  is 0 or 1 and compounds in which  $A$  is a thiazole,  $R^1$  is an amino group,  $B$  is a residue selected from substances of the following structural formulas

{0015}

{Chemical Formula 8}



(wherein  $R^1$  has the same significance as defined for general formula (I)),  $R^2$  is an aryl group, a cycloalkyl group or a phenylthio group,  $X$  is hydrogen, an amino group or a benzyloxycarbonylamino group,  $m$  is 4 or 5 and  $n$  is 0 or 1.

{0016} Desirable specific compounds of this invention include, for example, D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-pyrroline amide, D-cyclohexylalanyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-pyrroline amide, D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-octahydroindol e-2-carboxamide, D-phenylglycyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-proline amide, (benzyloxycarbonyl)-D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-proline amide, acetyl-D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-proline amide, phenylpropionyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-proline amide, 2-[N-[2-(phenylthioacetyl)cyclopenta-1-ylcarbonyl]-L-alginy]thiazole, D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-5-aminopentyl]-L-proline amide and D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-6-aminohexyl]-L-proline amide.


{0017} Stereoisomers attributable to the carbon atoms in the molecule can be present in the compounds of this invention. All stereoisomers are included in this invention. The compounds of this invention can be salts. These salts are salts that are pharmacologically permissible. Preferably, they can be salts of hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, maleic acid, succinic acid, lactic acid, tartaric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid.



[0018] The compounds of general formula (I) can be synthesized by various methods. For example, compounds of general formula (IV)

[0021] \*


[Chemical Formula 11]



(wherein, R<sup>1</sup>, R<sup>2</sup>, A, B, X, m and n have the same significances as defined previously) can be obtained by reacting compounds as indicated by general formula (II) below

[0019]


[Chemical Formula 9]



(wherein, R<sup>2</sup>, X, B and n have the same significances as defined in general formula (I) and X indicates a group having a protective group) and compounds as indicated by general formula (III) below

[0020]

[Chemical Formula 10]



(wherein, R<sup>1</sup>, A and m have the same significances as defined in general formula (I) and R<sup>1</sup> indicates a group having a protective group) with a suitable coupling reagent. When protective groups are necessary for R<sup>1</sup> and A in the synthesis, protective groups that are used in peptide chemistry can generally be used. Preferably, they can be t-butoxycarbonyl groups, benzyloxycarbonyl groups and 4-methoxy-2,3,6-trimethylbenzenesulfonyl groups.

[0022] Reagents that are used in peptide chemistry can be used as the coupling reagents. Desirable coupling reagents include, for example, N,N'-dicyclohexylcarbodiimide, 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide, benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate, N,N'-bis[2-oxo-3-oxazolidinyl]phosphonediamide acid chloride and diphenylphosphinyl chloride. In the presence of these reagents, the reaction can be performed in a suitable solvent (for example, ethyl acetate, acetonitrile, methylene chloride, DMF) at -70 to 30°C, and, preferably, -20 to 10°C.

[0023] Next, the hydroxyl group of compound (IV) is oxidized to form a ketone. As required, the protective group can be removed and the heterocyclic carbonyl compound of general formula (I) can be obtained. The oxidation reaction can be performed with dimethyl sulfoxide using various types of additives as described in Synthesis, 1990, page 857. Oxidation can also be performed by means of tetra-n-propylammonium perthenate (phonetic)\*\*, pyridinium dichromate and pyridinium chlorochromate. Oxidation by means of dimethyl sulfoxide in the presence of oxalyl chloride is preferable. For example, the compounds of general formula (I) can be obtained by reacting a reagent prepared from oxalyl chloride and dimethyl sulfoxide with compound (IV) at -70 to 0°C using methylene chloride as the solvent, after which treatment is performed with triethylamine.


[0024] Moderate reaction conditions can be selected to obtain compounds of general formula (I) when a reaction to eliminate protection is required. For example, when the protective groups described above are used, the protection can be eliminated by hydrocracking using palladium-carbon as the catalyst or by an acid decomposition reaction in which trifluoroacetic acid is reacted in the presence of anisole and thioanisole.

[0025] The compounds of general formula (I) of this invention form acid addition salts with various inorganic acids and organic acids. Compound (I) that is obtained by the aforementioned reactions can be isolated in free form or in the form of a salt. When it is in free form, the acid addition salt can be obtained by reaction with the desired acid.

[0026]\* In order to obtain the aforementioned amine compound (III), which is the starting substance, the carbinol compound (VII)

[0029]


[Chemical Formula 14]



can be obtained by reacting the aminocarbonyl compound (V), which is obtained by the method described in Chemical Review, 1989, Vol. 89, page 149.

[0027]

[Chemical Formula 12]




wherein R<sup>1</sup> and m have the same significances as defined in general formula (II) and Alloc indicates allyloxycarbonyl group) with the silyl compound (VIIa) described in Journal of Heterocyclic Chemistry, 1971, Vol. 8, page 257 and Journal of Organic Chemistry, 1988, Vol. 53, page 1748.

\*\*\*\*\*  
 \*\*Translator's note: Transliterated phonetically from the Japanese. As such, the spelling may differ from other transliterations.

[0028]

[Chemical Formula 13]



(wherein A has the same significances as defined in general formula (I)). Preferably, this reaction can be performed using methylene chloride as the solvent at 0 to 50°C in the presence or absence of cerium fluoride and tetrabutylammonium fluoride. Compound (VII) can also be obtained by treating the heterocyclic compound (H-A), which is the starting substance, with a base such as n-butyl lithium in an inactive solvent (for example, tetrahydrofuran and dimethoxyethane) to form compound (VIb):

[0030]


[Chemical Formula 15]



which is then reacted with the aforementioned compound (V). The aforementioned amine compound (III) can be obtained by treating and eliminating the amino group protective group of compound (VII), for example, pyrrolidine in the presence of  $\text{Pd}(\text{Ph}_3\text{P})_4$ , which is a known method. The aforementioned carboxylic acid compound (II), which is also a starting substance, can be obtained by ordinary methods of peptide chemistry when B-OH is an amino acid residue. Compound (II) can be obtained by introducing the carboxylic acid compound (VIII) into a reactive derivative (for example, an acid halide, an acid anhydride or an active ester) and by reacting it with an alkali metal salt of the amino acid (IX) or a salt of an organic base. Preferably, compound (VIII) can be reacted with N-hydroxysuccinic acid amide to convert it to an active ester which is then reacted with the amino acid (IX) in the presence of an organic base to form a peptide bond.

[0032]


[Chemical Formula 16]



When B-OH of the aforementioned compound (II) is an aliphatic carboxylic acid, it can be obtained from a cyclic or straight chain dicarboxylic acid. For example, with a cyclic dicarboxylic acid, the monoalkyl ester (1) is reacted with a thionyl chloride or oxalyl chloride to form an acid chloride (2a), which is then treated with diazomethane to convert it to diazomethyl ketone (2b). This ketone is reacted with anhydrous hydrogen chloride to form the chloromethyl ketone (2c), which is then converted to phenylthiomethyl ketone (3) by treating it with thiophenyl. The carboxylic acid compound (II) can be obtained by hydrolyzing the ester of this compound.

[0033]

[Chemical Formula 17]



(Wherein, R' indicates a methyl group, a benzyl group or a diphenylmethyl group.)

[0034] Because compound (I) of this invention and its acid addition salts exhibit a strong, selective inhibitory action against thrombin, it is useful as a diagnostic drug for determining thrombin in the blood, as a platelet coagulation inhibitor and in the prevention and treatment of thrombosis.

[0035] Thrombin inhibitors which contain compounds of this invention as indicated by general formula (I) and pharmacologically permissible salts thereof as their effective components can be used in various forms suited to oral and parenteral administration (for example, inhalation administration, nose drops, eye drops, subcutaneous administration, intravenous injection, intramuscular injection, etc.)

[0036] For example, depending on its intended use, they can be prepared as oral agents in such forms as tablets, capsules, granules, powders, fine grains, troches, syrups and emulsions, as inhalation agents, as solutions for topical use in the form of nose drops and eye drops and as injection agents for intravenous injection and intramuscular injection. These preparations can be manufactured by standard methods using vehicles, extending agents, binders, wetting agents, disintegrators, lubricants, dispersants, buffering agents, preservatives, auxiliary dissolution agents, antiseptics and stabilizers that are commonly used.

[0037] The content of the compound of this invention in a drug preparation differs depending on the form of the preparation. Ordinarily, it is 1 to 70 wt%, and, preferably, 5 to 50 wt %, of the total composition. The dose and the method of administration are determined appropriately taking into consideration the age and sex of the patient and the degree of symptoms. Ordinarily, for adults, it should be on the order of approximately 0.1 to 2000 mg, and, preferably, 5 to 400 mg, per day. It can be administered once or several times a day.

[0038] Method of determination of in vitro inhibitory activity

Thrombin inhibiting activity in an in vitro system was found by the method described in the European Journal of Biochemistry, 1988, Vol. 172, page 17. A mixed solution of 100 ml of 0.1 M tris(hydrochloric acid) solution (pH 8.0; containing 0.3 M NaCl and 2 mM CaCl<sub>2</sub>), a 10 ml DMSO solution of the compound of this invention, 50 ml of bovine serum albumin solution (0.4 mg/ml) and 20 ml of thrombin (0.5 U/ml) dissolved in the aforementioned tris(hydrochloric

acid solution was prepared. To this was added 20 ml of 5 mM Boc-Asp(OBzl)-Pro-Arg-methylcoumarin amide solution (10% DMSO), which was the substrate and the mixture was incubated for 30 minutes at 37°C, after which fluorescence intensity (a1) of 440 nm excited by 380 nm UV was determined. At the same time, an experiment was performed in which DMSO was used instead of the solution of the compound of this invention and fluorescence intensity (a2) was determined in the same way. In addition, the fluorescence intensity (b) of a mixed solution of 120 ml of the aforementioned 0.1 M tris(hydrochloric acid) buffer solution, 10 ml of DMSO solution, 50 ml of bovine serum albumin solution and 20 ml of substrate solution was determined as background. Inhibition rates were calculated by the following formula and the concentration required for 50% inhibition ( $IC_{50}$ ) was found.

$$\text{Inhibition rate (\%)} = \frac{[(a2-b) - (a1-b)]}{(a2-b)} \times 100$$

The experimental results for representative compounds of this invention are shown in Table 1.

Table 1. Thrombin Inhibition Activity

Example No. of compound	50% inhibition concentration
1	0.0015
2	0.15
4	0.012
5	1.32
7	0.007
8	0.002
Argatroban*	0.065

\* Compound described in Japanese Patent Disclosure No. 61-46629 (1986)

[0039]

[Examples] We shall now describe the compounds of this invention in detail by presenting examples as indicated below. However, they are simply illustrations and do not limit this invention in any way.

[0040] Example 1

D-phenylalanyl-N-[1-[(2-thiazolyl)carbamoyl]-4-guanidinobutyl]-L-proline amide

(a)

t-butoxycarbonyl-D-phenylalanyl-N-[1-[(2-thiazolyl)hydroxymethyl]-4-[N',N"-bis(t-butoxycarbonyl)aminoiminomethyl]amino]butyl]-L-proline amide

t-butoxycarbonyl-D-phenylalanyl-L-proline (300 mg, 0.82 mmol), 3-[2-amino-5-(N',N"-bis(t-butoxycarbonyl)aminoiminomethyl)amino-1-hydroxypentyl]thiazole (367 mg, 0.82 mmol) and N-hydroxybenzotriazole (110 mg, 0.82 mmol) were dissolved in 15 ml of acetonitrile and 1-ethyl-3-(3'-dimethylaminopropyl) carbodiimide hydrochloride (187 mg, 0.98 mmol) was added as the materials were being ice-cooled. The mixture was stirred at the same temperature for 3 hours. The temperature was then raised to room temperature and it was stirred for 15 hours. The reaction mixture was concentrated, after which it was dissolved in ethyl acetate, washed with water and dried in  $MgSO_4$ . The solvent was removed, the crude product was purified by flash chromatography and the target compound (497 mg, 77%) was obtained.

$^1H$ -NMR( $CDCl_3$ )  $\delta$  1.42-1.62 (m, 32H), 1.79-1.89 (m, 2H), 2.47-2.50 (m, 1H), 1.93-2.00 (m, 2H), 3.32-3.43 (m, 4H), 4.21-4.04 (m, 1H), 4.05-4.09 (m, 1H), 4.43-4.50 (m, 1H), 4.98-5.02 (m, 1H), 5.47-5.50 (m, 1H), 7.15-7.29 (m, 6H), 7.71-7.75 (m, 1H), 8.33-8.36 (m, 1H).

[0041] (b)

D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-proline amide

Oxazolyl chloride (79 ml, 0.91 mmol) was dissolved in 8 ml of methylene chloride, dimethyl sulfoxide (129 ml, 0.91 mmol) was added at -40°C and the mixture was stirred for 5 minutes. 5 ml of methylene chloride solution containing the aforementioned compound (480 mg, 0.61 mmol) was added and the mixture was stirred for 30 minutes at -40 to -30°C. Next, triethylamine (581 ml, 4.1 mmol) was added and the mixture was stirred at the same temperature for 30 minutes, after which it was emptied into ice water. The organic layer was separated and washed with water, after which it was desiccated with  $\text{MgSO}_4$  and concentrated. The product was refined by flash chromatography and t-butoxycarbonyl-D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-4-[N',N''-bis(t-butoxycarbonyl)aminoiminomethyl]amino]butyl]-L-proline amide (407 mg, 86%) was obtained. This compound was dissolved in 1 ml of anisole and 4 ml of trifluoroacetic acid was added as the materials were being ice cooled. The mixture was stirred at the same temperature for 30 minutes and was then stirred at room temperature for 30 minutes. The reaction mixture was concentrated, dissolved in 5 ml of water and washed with ether, after which it was freeze dried and the target substance (407 mg) was obtained.  $^1\text{H-NMR}(\text{D}_2\text{O})$   $\delta$  1.59-1.60 (m, 32H), 1.70-1.91 (m, 2H), 2.12-2.14 (m, 2H), 2.75-2.81 (m, 1H), 3.15-3.29 (m, 4H), 3.50-3.54 (m, 1H), 4.43-4.46 (m, 1H), 4.53-4.61 (m, 1H), 5.49-5.55 (m, 1H), 7.32-7.46 (m, 5H), 8.11-8.15 (m, 2H), MS (SIMS)  $m/z$  ( $\text{M}^+$ ).

[0042] (c) Synthesis of intermediate

The 2-[2-amino-5-[N',N''-bis(t-butoxycarbonyl)aminoiminomethyl]amino-1-hydroxypentyl]thiazole that was used in this example was synthesized by the following method. L-arginine (10 g, 57 mmol) was dissolved in 60 ml of water, allyl chloroformate (8.99 mg, 74 mmol) was added under ice-cooled conditions as the pH was maintained at 9 to 10 with 4N-NaOH, the pH was adjusted to 7 and the mixture was stirred at the same temperature for 2 hours. The precipitate that separated out was collected by filtration and was washed with a small quantity of ice water and acetone. It was then desiccated and N-allyloxycarbonyl-L-arginine (13.3 g, 90%) was obtained. The aforementioned compound (10 g, 39 mmol) and p-toluenesulfonic acid (7 g, 37 mmol) was dissolved in 250 ml of methanol, diphenyldiazomethane (15 g, 78 mmol) was added over a one hour period and the mixture was stirred for 3 hours at room temperature, after which it was concentrated. The reaction product was dissolved in chloroform and washed with water, after which it was desiccated with  $\text{MgSO}_4$  and concentrated, with N-allyloxycarbonyl-L-arginine diphenylmethyl ester p-toluenesulfonate (24 g) being obtained. The aforementioned crude product (24 g) was dissolved in 250 ml of acetonitrile, dimethylaminopyridine (4.7 g, 39 mmol) and bis-t-butyldicarbonate (21 g, 97 mmol) were added and the mixture was stirred for 15 hours at room temperature, after which it was concentrated. The reaction mixture was dissolved in ethyl acetate and washed in water, after which it was concentrated. It was then refined by silica gel chromatography (n-hexane/ethyl acetate) and N-allyloxycarbonyl-N',N''-bis(t-butoxycarbonyl)-L-arginine diphenyl methyl ester (14.5 g, 50%) was obtained.

[0043] The aforementioned compound (11 g, 18 mmol) was dissolved in 150 ml of tetrahydrofuran,  $\text{LiBH}_4$  (0.75 g, 35 mmol) was added and the mixture was stirred for 1 hour at room temperature. The reaction mixture was poured into acidic water at pH 3, extraction was performed with ethyl acetate and the organic layer was washed with water, after which it was desiccated with  $\text{MgSO}_4$  and concentrated. The reaction product was refined by silica gel chromatography (n-hexane/ethyl acetate) and N-allyloxycarbonyl-N',N''-bis(t-butoxycarbonyl)-L-arginol (3.9 g, 50%) was obtained.

$^1\text{H-NMR}(\text{CDCl}_3)$   $\delta$  1.35-1.80 (m, 22H), 3.30-3.80 (m, 6H), 4.58 (d, J = 5.02 Hz, 1H), 5.22 (dd, J = 1.55, 10.0 Hz, 1H), 5.31 (dd, J = 1.55, 17.6 Hz, 1H), 5.49 (d, J = 7.53 Hz, 1H), 5.93 (ddd, J = 5.02, 10.0, 17.6 Hz, 1H), 8.38

(t, J = 5.02 Hz, 1H). Oxazoliyl chloride (1.27 g, 10 mmol) was dissolved in 40 ml of methylene chloride, dimethyl sulfoxide (1.57 g, 20 mmol) was added at -30°C, after 5 minutes, 20 ml of methylene chloride solution containing the aforementioned carbinol compounds (3.0 g, 6.7 mmol) was added and the mixture was stirred for 30 minutes at -30°C. Next, triethylamine (4.62 g, 45 mmol) was added and the mixture was stirred for 30 minutes at -30°C, after which it was emptied into ice water and the solutions were separated. The organic layer was washed with water, after which it was desiccated with MgSO<sub>4</sub> and concentrated, with N-allyloxycarbonyl-N',N'-bis(t-butoxycarbonyl)-L-arginine (2.9 g) being obtained.

[0044] The aforementioned crude product (2.9 g) and 2-trimethylsilylthiazole (1.54 mg, 9.8 mmol) were dissolved in 50 ml of methylene chloride and the solution was stirred for 5 hours at room temperature. 1M tetra-n-butylammonium fluoride THF solution (10.4 ml) was added, the mixture was stirred for another 30 minutes and was then emptied into ice water. The organic layer was separated, desiccated with MgSO<sub>4</sub> and concentrated. It was then refined by silica gel chromatography (n-hexane/ethyl acetate) and 2-[2-allyloxycarbonylamino-5-[N',N'-bis(t-butoxycarbonyl)aminoiminomethyl]amino-1-hydroxypentyl]thiazole (2.1 g, 60%) was obtained.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.35-1.86 (m, 22H), 3.30-3.55 (m, 2H), 4.05-4.22 (m, 1H), 4.43-4.65 (m, 2H), 5.06-5.40 (m, 4H), 5.78-6.02 (m, 2H), 7.28 (d, J = 3.0 Hz, 1H), 7.73 (d, J = 3.0 Hz, 1H), 8.48 (t, J = 6.24 Hz, 1H).

[0045] The aforementioned compound (2.1 g) was dissolved in 35 ml of methylene chloride, piperidine (1.34 g, 19 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (220 mg, 0.19 mmol) was added and the mixture was stirred for 30 minutes at room temperature. The reaction mixture was concentrated and refined by silica gel chromatography (chloroform/methanol), with the target compound (1.42 g, 85%) being obtained.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.40-1.80 (m, 22H), 3.17-3.55 (m, [sic] 4.70-4.80 (m, 1H), 4.88-4.98 (m, 1H), 7.40-7.80 (m, 3H), 8.30-8.43 (m, 1H).

[0046] Example 2

## 2-[2-[2-(phenylthioacetyl)cyclopenta-1-ylcarbonyl]-L-arginyl]thiazole

(a)

2-[2-[2-(phenylthioacetyl)cyclopenta-1-ylcarbonyl]amino-5-[N',N'-bis(t-butoxycarbonyl)aminoiminomethyl]amino-1-hydroxypentyl]thiazole

2-(phenylthioacetyl)cyclopentanecarboxylic acid (249 mg, 0.94 mmol), 2-[2-amino-5-[N',N'-bis(t-butoxycarbonyl)aminoiminomethyl]amino-1-hydroxypentyl]thiazole (417 mg, 0.94 mmol) and N-hydroxybenzotriazole (126 mg, 0.94 mmol) were dissolved in 20 ml of acetonitrile, 1-ethyl-3-(3'-dimethylaminopropyl) carbodiimide hydrochloride (215 mg, 0.98 mmol) was added under ice-cooled conditions, the mixture was stirred at this same temperature for 3 hours, the temperature was then raised to room temperature and it was stirred for 15 hours. The reaction mixture was concentrated, after which it was dissolved in ethyl acetate. It was then washed with water, after which it was desiccated with MgSO<sub>4</sub>. The solvent was removed, the crude product was refined by flash chromatography and the target compound (438 mg, 68%) was obtained.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.20-2.10 (m, 28H), 2.97 (m, 1H) 3.30-3.50 (m, 3H), 3.24 (m, 1H), 4.25 (m, 1H), 5.03 (m, 1H), 6.75 (m, 1H), 7.15-7.40 (m, 5H), 7.43-7.57 (m, 1H), 7.70 (m, 1H), 8.37 (m, 1H).

[0047] (b) 2-[2-(phenylthioacetyl)cyclopentane-1-ylcarbonyl]-L-arginyl]thiazole oxalyl chloride (81 ml, 0.93 mmol) was dissolved in 10 ml of methylene chloride, dimethyl sulfoxide (132 ml, 1.87 mmol) was added at -40°C and the mixture was stirred for 5 minutes. 5 ml of methylene chloride solution containing the aforementioned compound (430 mg, 0.62 mmol) was added and the mixture was stirred for 30 minutes at -40 to -30°C. Next, triethylamine (596 ml, 4.2 mmol) was added and the mixture was stirred at this same

temperature for 30 minutes, after which it was emptied into ice water. The organic layer was separated and washed with water, after which it was desiccated with  $\text{MgSO}_4$  and concentrated. The product was purified by flash chromatography and

2-[(2-(phenylthioacetyl)cyclopentane-1-ylcarbonyl-N',N'-bis(t-butoxycarbonyl) arginyl]thiazole (350 mg, 83%) was obtained. This compound was dissolved in 1 ml of anisole, 4 ml of trifluoroacetic acid was added under ice-cooled conditions, the mixture was stirred at this same temperature for 30 minutes and was then stirred for 30 minutes at room temperature. The reaction mixture was concentrated and refined by flash chromatography (chloroform/methanol), with the target compound (254 mg) being obtained.

$^1\text{H-NMR}(\text{CD}_3\text{OD})$   $\delta$  1.60-2.20 (m, 10H), 3.05 (m, 1H), 3.24 (m, 2H), 3.53 (m, 1H), 3.90 (m, 2H), 5.56 (m, 1H), 7.10-7.40 (m, 1H), 7.10-7.40 (m, 5H), 8.05 (m, 1H), 8.12 (m, 1H), MS(ED)  $m/z$  488 ( $\text{M}^+$ ).

#### [0048] (c) Synthesis of intermediate

The 2-phenylthiomethylcarbonylcyclopentane-1-carboxylic acid that was used in this example was synthesized by the following method.

2-[(diphenyl) methoxycarbonyl]cyclohexane-1-carboxylic acid (2.0 g, 6.17 mmol) and triethylamine (0.944 ml, 6.79 mmol) were dissolved in 20 ml of methylene chloride, N,N-dimethylformamide (1 drop) and oxalyl chloride (855 mg, 6.79 mmol) were added under ice-cooled conditions and the mixture was stirred for 1 hour. Next, an ether solution containing an excess of diazomethane was added under ice-cooled conditions and the mixture was stirred for 30 minutes. A 4N-HCl dioxane solution (2.31 ml) was then added and the mixture was stirred for another 30 minutes. The reaction product was concentrated, the chloromethyl ketone that was produced was dissolved in 30 ml of tetrahydrofuran, diisopropyl ethylamine (815 mg, 6.32 mmol) and thiophenol (690 mg, 6.32 mmol) were added and the mixture was stirred for 3 hours at room temperature, after which it was concentrated. The reaction product was refined by silica gel chromatography (toluene/acetic acid) and phenylthiomethyl ketone (2.12 g, 86%) was obtained. This product was dissolved in 200 ml of methanol, a 1M aqueous solution of potassium carbonate (9.74 ml) was added and the mixture was stirred for 15 hours at room temperature. The reaction mixture was concentrated and the residue was dissolved in water and washed with ether. The aqueous layer was acidified, after which extraction was performed with ethyl acetate. It was then desiccated with  $\text{MgSO}_4$  and concentrated, with the target compound (0.97 g, 76%) being obtained.

$^1\text{H-NMR}(\text{CDCl}_3)$   $\delta$  1.60-2.10 (m, 6H), 3.20 (m, 1H), 3.58 (m, 1H), 3.80 (s, 2H), 7.15-7.40 (m, 5H).

#### [0049] Example 3

##### 2-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-5-aminopentyl]-L-proline amide

(a) t-butoxycarbonyl-D-phenylalanyl-N-[1-(2-thiazolyl)hyroxymethyl]-5-(benzyloxycarbonylamino)pentyl]-L-proline amide, t-butoxycarbonyl-D-phenylalanyl-L-proline (255 mg, 0.70 mmol), 2-[2-amino-6-(benzyloxycarbonyl) amino-1-hydroxybenzotriazole (94 mg, 0.70 mmol) and N-hydroxybenzotriazole (94 mg, 0.70 mmol) were dissolved in 15 ml of acetonitrile, 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (160 mg, 0.84 mmol) was added under ice-cooled conditions, the mixture was stirred at this same temperature for 3 hours, the temperature was raised to room temperature and the mixture was then stirred for 15 hours. The reaction mixture was concentrated, after which it was dissolved in ethyl acetate. It was then washed with water, after which it was desiccated with  $\text{MgSO}_4$ . The solvent was removed, the crude product was refined by flash chromatography (ethyl acetate) and the target compound (393 mg, 81%) was obtained.

$^1\text{H-NMR}(\text{CDCl}_3)$   $\delta$  1.20-2.15 (m, 20H), 2.40-2.80 (m, 1H), 2.90-3.47 (m, 3H), 3.55-3.77 (m, 1H), 4.23-4.58 (m, 3H), 4.95-5.04 (m, 2H), 5.04-5.30 (m, 2H), 5.30-5.56 (m, 2H), 7.04-7.90 (m, 12H).



[0050] (b) D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-5-aminopentyl]-L-proline amide

Oxalyl chloride (72 ml, 0.84 mmol) was dissolved in 3 ml of methylene chloride, dimethyl sulfoxide (119 ml, 1.68 mmol) was added at -40°C and the mixture was stirred for 5 minutes. 5 ml of methylene chloride solution containing the aforementioned compound (390 mg, 0.56 mmol) was added and the mixture was stirred for 30 minutes at -40 to -30°C. Next, triethylamine (394 ml, 2.81 mmol) was added and the mixture was stirred for 30 minutes at this same temperature, after which it was emptied into ice water. The organic layer was separated and washed with water, after which it was desiccated with MgSO<sub>4</sub> and concentrated. The product was refined by flash chromatography (hexane/ethyl acetate) and t-butoxycarbonyl-D-phenylalanyl-N-[1-[(2-thiazolyl) carbonyl]-5-(benzyloxycarbonyl)aminopentyl]-L-proline amide (388 mg, 73%) was obtained. This compound was dissolved in formic acid (3.5 ml), Pd (150 mg) was added and the mixture was stirred for 3 hours at room temperature. The reaction mixture was filtered, after which the filtrate was concentrated, the product was dissolved in 1 ml of anisole, trifluoroacetic acid (3 ml) was added under ice-cooled conditions and the mixture was stirred at this same temperature for 30 minutes. The reaction mixture was concentrated and was dissolved in 5 ml of water. It was then washed with water, after which freeze-drying was performed and the target substance (190 mg) was obtained.

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.25-2.04 (m, 7H), 2.04-2.18 (m, 1H), 2.64-2.82 (m, 2H), 3.00-3.70 (m, 6H), 4.30-4.45 (m, 2H), 5.45-5.55 (dd, J = 4.14, 9.31 Hz, 1H), 7.20-7.55 (m, 5H), 7.70-8.20 (m, 2H); MS(FD) m/z 458 (M<sup>+</sup>).

[0051] (c) Synthesis of intermediate

The 2-[2-amino-6-(benzyloxycarbonyl)amino-1-hydroxyhexyl]thiazole that was used in this example was synthesized by the same method as in Example 1c using N $\alpha$ -allyloxycarbonyl-N $\omega$ -benzyloxycarbonyl-L-lysine methyl ester as the starting substance.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.20-1.80 (m, 6H), 1.80-1.96 (m, 1H), 3.10-3.34 (m, 3H), 3.60-3.80 (m, 1H), 4.70 (d, J = 3.78 Hz, 1H), 4.80-4.97 (m, 1H), 5.01 (s, 2H), 7.29 (d, J = 2.52 Hz, 1H), 7.30-7.38 (m, 5H), 7.73 (d, J = 2.52 Hz, 1H).

[0052] Example 4

D-cyclohexylalanyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-proline amide

It was synthesized by the same method as in Example 1 from t-butoxycarbonyl-D-cyclohexylalanyl-L-proline and the compound of Example 1c.

<sup>1</sup>H-NMR (D<sub>2</sub>O) δ 1.00-1.55 (m, 4H), 1.55-2.25 (m, 14H), 2.30-2.40 (m, 1H), 3.22-3.30 (m, 2H), 3.58-3.70 (m, 1H), 3.72-3.82 (m, 1H), 4.39 (dd, J = 3.45, 13.8 Hz, 1H), 4.56 (dd, J = 8.6 Hz, 1H), 4.80-5.80 (m, 1H), 8.10-8.23 (m, 2H), MS (SIMS) m/z 492 (M<sup>+</sup>).

[0053] Example 5

D-phenylglycyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-proline amide

It was synthesized by the same method as in Example 1 from t-butoxycarbonyl-D-phenylglycyl-L-proline and the compound of Example 1c.

<sup>1</sup>H-NMR (D<sub>2</sub>O) δ 1.62-1.97 (m, 8H), 2.10-2.20 (m, 1H), 2.98-3.06 (m, 1H), 3.22-3.30 (m, 1H), 3.63-3.72 (m, 1H), 4.58 (dd, J = 3.40, 8.60 Hz, 1H), 5.38-5.43 (m, 1H), 5.50-5.60 (m, 1H), 7.45-7.60 (m, 5H), 8.10 (d, 1H), 8.20 (d, 1H); MS (SIMS) m/z 472 (M<sup>+</sup>).

[0054] Example 6

D-tyrosyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-proline amide

It was synthesized by the same method as in Example 1 from t-butoxycarbonyl-D-tyrosyl-L-proline and the compound of Example 1c.

<sup>1</sup>H-NMR (D<sub>2</sub>O) δ 1.75-2.04 (m, 6H), 2.16-2.36 (m, 2H), 3.04-3.10 (m, 1H), 3.25-3.28 (m, 6H), 3.45-3.46 (m, 1H), 3.70-3.76 (m, 1H), 4.52-4.77 (m, 2H), 5.52-5.56 (m, 1H), 6.85-6.96 (m, 2H), 7.19-7.26 (m, 2H), 8.13-8.19 (m, 2H), MS (SIMS) m/z 504 (M<sup>+</sup>).

[0055] Example 7

D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-octahydroindole-2-carboxamide

It was synthesized by the same method as in Example 1 from t-butoxycarbonyl-D-phenylalanyl-L-octahydroindole-2-carboxylic acid and the compound of Example 1c.

<sup>1</sup>H-NMR (D<sub>2</sub>O) δ 0.87-1.05 (m, 2H), 1.10-1.23 (m, 3H), 1.36-1.49 (m, 3H), 1.58-1.82 (m, 5H), 1.91-2.03 (m, 2H), 2.85-3.00 (m, 2H), 3.15-3.20 (m, 3H), 4.20-4.25 (m, 1H), 4.34 (dd, J = 5.4, 10.3 Hz, 1H), 5.38 (dd, J = 4.0, 8.4 Hz, 1H), 7.19-7.36 (m, 5H), 7.98-8.04; MS (SIMS) m/z 540 (M<sup>+</sup>).

[0056] Example 8

Benzylloxycarbonyl-D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-proline amide

It was synthesized in the same way as in Example 1 from benzylloxycarbonyl-D-phenylalanyl-L-proline and the compound of Example 1c.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 1.40-2.20 (m, 7H), 2.59-2.80 (m, 1H), 2.90-3.50 (m, 5H), 3.50-3.80 (m, 1H), 4.28-4.54 (m, 1H), 4.54-4.70 (m, 1H), 5.04 (ABq, J = 13.8, 39.7 Hz, 1H), 5.45-5.70 (m, 1H), 6.18-6.30 (m, 1H), 6.90-7.50 (m, 10H), 7.65 (d, J = 7.35 Hz, 1H), 7.84 (d, J = 7.35 Hz, 1H), 7.94-8.04 (m, 1H); MS (SIMS) m/z 620 (M<sup>+</sup>).

## [0057] Example 9

Acetyl-D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-proline amide

It was synthesized in the same way as in Example 1 from acetyl-D-phenylalanyl-L-proline and the compound of Example 1c.

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.50-2.50 (m, 11H), 2.52-2.75 (m, 2H), 2.97-3.13 (m, 2H), 3.15-3.50 (m, 2H), 3.65-3.80 (m, 1H), 4.35-4.50 (m, 1H), 5.35-5.50 (m, 1H), 7.23-7.56 (m, 5H), 8.00-8.22 (m, 2H), MS(SIMS) m/z 528 (M<sup>+</sup>).

## [0058] Example 10

3-phenylpropionyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-proline amide

It was synthesized by the same method as in Example 1 from 3-phenylpropionyl-L-proline and the compound of Example 1c

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.50-2.50 (m, 6H), 2.50-3.25 (m, 8H), 3.25-3.57 (m, 2H), 4.28-4.38 (m, 1H), 5.40-5.46 (m, 1H), 7.20-7.40 (m, 5H), 7.60-7.70 (m, 1H), 8.00-8.10 (m, 1H); MS(SIMS) m/z 471 (M<sup>+</sup>).

## [0059] Example 11

4-phenylbutanoyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-proline amide

It was synthesized in the same way as in Example 1 from 4-phenylbutanoyl-L-proline and the compound of Example 1c.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.72-1.75 (m, 2H), 1.89-2.09 (m, 5H), 2.26-2.51 (m, 5H), 2.61-2.68 (m, 2H), 3.13-3.56 (m, 4H), 4.42-4.53 (m, 1H), 5.59 (brs, 1H), 7.08-7.28 (m, 5H), 7.70 (d, J = 3.1 Hz, 1H), 7.77-7.90 (m, 2H), 8.00 (d, J = 3.1 Hz, 1H), MS(SIMS) m/z = 485 (M<sup>+</sup>).

## [0060] Example 12

D-propyl-N-[1-[(2-thiazolyl)carbonyl]-4-guanidinobutyl]-L-proline amide

It was synthesized in the same way as in Example 1 from t-butoxycarbonyl-D-pyrrolyl-L-proline and the compound of Example 1c.

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.70-2.20 (m, 9H), 2.30-2.45 (m, 1H), 2.47-2.65 (m, 2H), 3.25-3.35 (m, 1H), 3.40-3.55 (m, 2H), 3.60-3.68 (m, 1H), 3.70-3.80 (m, 1H), 3.80-3.90 (m, 1H), 4.58 (dd, J = 3.40, 5.17 Hz, 1H), 4.68 (dd, J = 6.90, 7.59 Hz, 1H), 5.51 (dd, J = 5.17, 9.31 Hz, 1H), 8.12 (d, J = 3.40 Hz, 1H), 8.18 (d, J = 3.40 Hz, 1H); MS(FD) m/z 435 (M<sup>+</sup>).

## [0061] Example 13

2-[2-(phenylthioacetyl)cyclohexa-1-ylcarbonyl-L-arginyl]thiazole

It was synthesized in the same method as in Example 2 from 2-(phenylthioacetyl)cyclohexanecarboxylic acid and the compound from Example 1c.

<sup>1</sup>H-NMR(CD<sub>3</sub>OD) δ 1.10-2.20 (m, 12H), 2.63 (m, 1H), 3.02 (m, 1H), 3.09-3.23 (m, 2H), 3.93-4.09 (m, 2H), 5.47-5.55 (m, 1H), 7.05-7.40 (m, 5H), 8.02 (m, 1H), 8.10 (m, 1H); MS(SIMS) m/z 502 (M<sup>+</sup>).

## [0062] Example 14

4-phenylbutanoyl-N-[1-[(2-thiazolyl)carbonyl]-5-aminopentyl]-L-proline amide

It was synthesized in the same method as in Example 3 from 4-phenylbutanoyl-L-proline and the compound of Example 3c.

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.40-2.25 (m, 10H), 2.35 (m, 2H), 2.65 (m, 2H), 2.99 (m, 2H), 3.42-3.52 (m, 4H), 4.40 (m, 1H), 5.46 (m, 1H), 7.10-7.40 (m, 5H), 8.05 (m, 1H), 8.11 (m, 1H); MS(SIMS) m/z 457 (M<sup>+</sup>).

## [0063] Example 15

3-phenylpropionyl-N-[1-[(2-thiazolyl)carbonyl]-5-aminopentyl]-L-proline amide

It was synthesized in the same method as in Example 3 from 3-phenylpropionyl-L-proline and the compound of Example 3c.

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.20-1.90 (m, 7H), 1.90-2.20 (m, 2H), 2.50-3.00 (m, 5H), 3.20-3.54 (m, 2H), 4.29-4.37 (m, 1H), 5.39 (dd, J = 3.75, 8.00 Hz, 1H), 7.12-7.35 (m, 5H), 7.98 (d, J = 2.77 Hz, 1H), 8.06 (d, J = 2.77 Hz, 1H); MS(SIMS) m/z 443 (M<sup>+</sup>).

## [0064] Example 16

D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-6-aminohexyl]-L-proline amide

It was synthesized in the same method as in Example 3 from t-butoxycarbonyl-D-phenylalanyl-L-proline and 2-[2-amino-7-(benzyloxycarbonyl)amino-1-hydroxypentyl]thiazole.

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.20-1.90 (m, 9H), 2.00-2.20 (m, 2H), 2.74 (ddd, J = 6.90, 7.24, 7.59 Hz, 1H), 2.98-3.10 (m, 2H), 3.10-3.32 (m, 2H), 3.39-3.50 (m, 1H), 4.44 (dd, J = 4.83, 9.66 Hz, 1H), 4.50-4.60 (m, 1H), 5.48 (dd, J = 4.14, 9.66 Hz, 1H), 7.25-7.50 (m, 5H), 8.10 (d, J = 2.41 Hz, 1H), 8.15 (d, J = 2.41 Hz, 1H); MS(SIMS) m/z 471 (M<sup>+</sup>).

## [0065] Example 17

3-phenylpropionyl-N-[1-[(2-thiazolyl)carbonyl]-6-aminohexyl]-L-proline amide

It was synthesized in the same method as in Example 3 from 3-phenylpropionyl-L-proline and 2-[2-amino-7-(benzyloxycarbonyl)amino-1-hydroxyheptyl]thiazole.

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.20-1.90 (m, 10H), 1.90-2.08 (m, 1H), 2.08-2.30 (m, 1H), 2.54-2.85 (m, 1H), 2.85-3.06 (m, 6H), 3.25-3.35 (m, 1H), 3.40-3.61 (m, 2H), 4.41 (d, J = 6.90 Hz, 1H), 5.43 (dd, J = 3.45, 8.60 Hz, 1H), 7.14-7.37 (m, 5H), 8.02 (d, J = 2.4 Hz, 1H), 8.08 (d, J = 2.4 Hz, 1H); MS(FD) m/z 456 (M<sup>+</sup>).

## [0066] Example 18

D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-4-methoxybutyl]-L-proline amide

It was synthesized in the same method as in Example 1 from t-butoxycarbonyl-D-phenylalanyl-L-proline and 2-(2-amino-1-hydroxy-5-methoxypentyl)thiazole.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.57-1.59 (m, 1H), 1.73-1.88 (m, 5H), 2.07-2.14 (m, 2H), 2.75-2.78 (m, 1H), 3.20-3.33 (m, 2H), 3.35 (s, 3H), 3.49-3.56 (m, 3H), 4.42 (dd, J = 4.2, 8.5 Hz, 1H), 4.53 (m, 1H), 5.49 (dd, J = 4.3, 8.4 Hz, 1H), 7.31-7.34 (m, 2H), 7.41-7.46 (m, 3H), 8.09 (d, J = 3.1 Hz, 1H), 8.14 (d, J = 3.1 Hz, 1H); MS(FD) m/z = 459 (M<sup>+</sup>).

## [0067] Example 19

D-phenylalanyl-N-[1-[(2-benzothiazolyl)carbonyl]-4-methoxybutyl]-L-proline amide

It was synthesized in the same method as in Example 1 from t-butoxycarbonyl-D-phenylalanyl-L-proline and 2-(2-amino-1-hydroxy-5-methoxypentyl)benzothiazole.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.74-1.78 (m, 1H), 1.80-1.93 (m, 4H), 2.04-2.19 (m, 2H), 2.73-2.74 (m, 1H), 3.15-3.28 (m, 2H), 3.35 (s, 3H), 3.54-3.58 (m, 4H), 4.40-4.45 (m, 1H), 4.50-4.54 (m, 1H), 5.56 (dd, J = 4.3, 8.4 Hz, 1H), 7.24-7.43 (m, 5H), 7.67-7.73 (m, 2H), 8.15-8.26 (m, 2H); MS(SIMS) m/z = 509 (M<sup>+</sup>).

## [0068] Example 20

t-butoxycarbonyl-D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-4-methoxybutyl]-L-proline amide

It was synthesized from t-butoxycarbonyl-D-phenylalanyl-L-proline and 2-(2-amino-1-hydroxy-5-methoxypentyl)thiazole and was obtained as the intermediate of Example 18.

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.51-1.90 (m, 14H), 2.15-2.23 (m, 2H), 2.62-2.66 (m, 1H), 3.01-3.04 (m, 2H), 3.30 (s, 3H), 3.38-3.44 (m, 3H), 3.54-3.57 (m, 1H), 4.49-4.62 (m, 2H), 5.40-5.43 (m, 1H), 5.75-5.79 (m, 1H), 7.18-7.32 (m, 5H), 7.53-7.61 (m, 2H), 7.95-7.98 (m, 1H), 8.18-8.21 (m, 1H); MS(FD) m/z 558 (M<sup>+</sup>).

## [0069] Example 21

t-butoxycarbonyl-D-phenylalanyl-N-[1-[(2-benzothiazolyl)carbonyl]-4-methoxybutyl]-L-proline amide

It was synthesized from t-butoxycarbonyl-D-phenylalanyl-L-proline and 2-(2-amino-1-hydroxy-5-methoxypentyl)benzothiazole and was obtained as the intermediate of Example 19.

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.43 (s, 9H), 1.51-1.67 (m, 4H), 1.80-1.89 (m, 2H), 2.07-2.21 (m, 2H), 2.61-2.63 (m, 1H), 2.90-3.05 (m, 2H), 3.30 (s, 3H), 3.33-3.40 (m, 2H), 3.51-3.54 (m, 1H), 4.44-4.68 (m, 1H), 4.62-4.64 (m, 1H), 5.44-5.47 (m, 1H), 5.55-5.62 (m, 1H), 7.20-7.31 (m, 5H), 7.63-7.65 (m, 1H), 7.68 (d, J = 3.0 Hz, 1H), 8.02 (d, J = 3.0 Hz, 1H); MS(FD) m/z 608 (M<sup>+</sup>).

## [0070] Example 22

D-phenylalanyl-N-[1-[(2-thiazolyl)carbonyl]-2-phenylethyl]-L-proline amide

It was synthesized by the same method as in Example 1 from t-butoxycarbonyl-D-phenylalanyl-L-proline and 2-(2-amino-1-hydroxy-3-phenylpropyl)thiazole.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.49-1.54 (m, 2H), 1.60-1.80 (m, 1H), 2.10-2.14 (m, 1H), 2.59-2.67 (m, 1H), 2.85-2.97 (m, 2H), 3.10-3.19 (m, 1H), 3.28-3.49 (m, 2H), 3.64-3.75 (m, 1H), 4.50-4.54 (m, 1H), 5.88-5.93 (m, 1H), 7.20-7.36 (m, 10H), 7.67-7.78 (m, 2H), 8.06-8.08 (m, 1H); MS(SIMS) m/z = 477 (M<sup>+</sup>).

[0071] Example 23

4-phenylbutanoyl-N-[1-[(2-thiazolyl)carbonyl]ethyl]-L-proline amide

It was synthesized by the same method as in Example 1 from 4-phenylbutanoyl-L-proline and 2-(2-amino-1-hydroxypropyl)thiazole.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  1.52 (d,  $J$  = 6.90 Hz, 1H), 1.80-2.30 (m, 6H), 2.30-2.38 (m, 2H), 2.68-2.74 (m, 2H), 3.30-3.40 (m, 1H), 3.45-3.52 (m, 1H), 4.62 (dd,  $J$  = 2.41, 9.31 Hz, 1H), 5.69 (q,  $J$  = 6.90 Hz, 1H), 7.18-7.31 (m, 5H), 7.69 (d,  $J$  = 3.10 Hz, 1H), 8.02 (d,  $J$  = 3.10 Hz, 1H); MS (FD)  $m/z$  = 399 ( $M^+$ ).

(19) 日本国特許庁 (J P)

(12) 公開特許公報 (A)

(11) 特許出願公開番号

特開平8-20597

(43) 公開日 平成 8 年 (1996) 1 月 23 日

(51) Int. CL <sup>4</sup>	識別記号	庁内整理番号	F I	技術表示箇所
C 0 7 K 5/06		8318-4H		
C 0 7 D 27/28				
27/56				
471/12				

審査請求 未請求 請求項の数 3 O L (全 13 頁)

(21) 出願番号 特願平6-156006

(22) 出願日 平成 6 年 (1994) 7 月 7 日

(71) 出願人 000006091

明治製菓株式会社

東京都中央区京橋 2 丁目 4 番 16 号

(72) 発明者 小此木 恒夫

神奈川県横浜市港北区師岡町 760 番地 明

治製菓株式会社薬品総合研究所内

(72) 発明者 堤 誠司

神奈川県横浜市港北区師岡町 760 番地 明

治製菓株式会社薬品総合研究所内

(72) 発明者 秋山 佳夫

神奈川県横浜市港北区師岡町 760 番地 明

治製菓株式会社薬品総合研究所内

最終頁に続く


(54) 【発明の名称】 トロンピン阻害作用を有する複素環カルボニル化合物

(57) 【要約】

【目的】

【構成】 本発明は、トロンピンに対し阻害活性を有し、血栓症の予防や治療に用いられる一般式 (I) で表される化合物並びにその薬理学的許容される塩に関する。

【化 18】



【式中、Aは複素環式基、R<sup>1</sup>はアルキル基、グアニジノ基、アミジノ基、アミジノチオ基、アミノ基、水酸基、メルカプト基、低級アルコキシ基、置換されていてよいフェニル基、Bはアミノ酸残基、R<sup>2</sup>はメチル基、シクロアルキル基、アリール基、ヘテロアリール基、アリールチオ基、Xは水素原子、水酸基、アミノ基、ハロゲン原子、アルキルアミノ基、アシルアミノ基、アルコキシカルボニルアミノ基、mは1～5の整

(19) 日本国特許庁 (J P)

(12) 公開特許公報 (A)

(11) 特許出願公開番号

特開平8-20597

(43) 公開日 平成8年(1996)1月23日

(51) IntCl. <sup>6</sup>	識別記号	庁内整理番号	F I	技術表示箇所
C 0 7 K 5/06		8318-4H		
C 0 7 D 277/28				
277/56				
471/12				

審査請求 未請求 請求項の数 3 O L (全 13 頁)

(21) 出願番号 特願平6-156006

(22) 出願日 平成6年(1994)7月7日

(71) 出願人 000006091

明治製菓株式会社

東京都中央区京橋2丁目4番16号

(72) 発明者 小此木 恒夫

神奈川県横浜市港北区師岡町760番地 明

治製菓株式会社薬品総合研究所内

(72) 発明者 堤 誠司

神奈川県横浜市港北区師岡町760番地 明

治製菓株式会社薬品総合研究所内

(72) 発明者 秋山 佳央

神奈川県横浜市港北区師岡町760番地 明

治製菓株式会社薬品総合研究所内

最終頁に続く


(54) 【発明の名称】 トロンビン阻害作用を有する複素環カルボニル化合物

(57) 【要約】

【目的】

【構成】 本発明は、トロンビンに対し阻害活性を有し、血栓症の予防や治療に用いられる一般式 (I) で表される化合物並びにその薬理学的許容される塩に関する。

【化18】



〔式中、Aは複素環式基、R<sup>1</sup>はアルキル基、グアニジノ基、アミジノ基、アミジノチオ基、アミノ基、水酸基、メルカプト基、低級アルコキシ基、置換されていてもよいフェニル基、Bはアミノ酸残基、R<sup>2</sup>はメチル基、シクロアルキル基、アリール基、ヘテロアリール基、アリールチオ基、Xは水素原子、水酸基、アミノ基、ハロゲン原子、アルキルアミノ基、アシルアミノ基、アルコキシカルボニルアミノ基、mは1~5の整数、nは0~4の整数をそれぞれ示す〕




1


【特許請求の範囲】

【請求項1】 下記の一般式(1)で表される複素環カルボニル化合物およびその薬理学的に許容される塩。

【化1】




[式中、Aは少なくとも1個の窒素原子を有する5員環もしくは6員環の飽和、部分飽和または不飽和である単環式複素環、またはベンゼン環もしくはピリジン環が縮合している二環式複素環(上記複素環は酸素原子、イオウ原子または別途3個以下の窒素原子を有してもよく、\*



(R<sup>3</sup>は水素、炭素数1~6の分岐してもよいアルキル基、フェニル基、フェニルメチル基である)を示し、R<sup>2</sup>はメチル基、アリール基、シクロアルキル基、ヘテロアリール基、アリールチオ基、Xと結合しているメチレンを示し、Xは水素原子、水酸基、アミノ基、ハロゲン原子、炭素数1~4のアルキルアミノ基、アシルアミノ基、アルコキシカルボニルアミノ基、アリールオキシカルボニルアミノ基を示し、mは1~5の整数を示し、nは0~4の整数を示す。]

【請求項2】 請求項1の一般式(1)において、Aはチアゾール、オキサゾール、イミダゾール、チアゾリン、オキサゾリン、イミダゾリン、ピリジン、ピリミジン、ピラゾール、1,2,4-チアジアゾール、1,2,4-オキサジア※



(R<sup>3</sup>は一般式(1)で定義したものと同じ意味を表す)を示し、R<sup>2</sup>はメチル基、置換基を有してもよいフェニル

2

\*単環式複素環では環内の炭素原子または二環式複素環ではベンゼン環もしくはピリジン環の炭素原子に炭素数1~4の低級アルキル基、ハロゲン、水酸基、アミノ基、メルカプト基で置換してもよく、また複素環を構成している何れかの炭素原子を介してカルボニル基に結合している)を示し、R<sup>1</sup>は炭素数1~4の分岐してもよいアルキル基、グアニジノ基、アミジノチオ基、アミジノ基、アミノ基、水酸基、メルカプト基、低級アルコキシ基、もしくはグアニジノ基、アミジノ基、アミノ基、水酸基、メルカプト基、ハロゲンで置換されてもよいフェニル基を示し、Bは以下から選択される残基

【化2】

※ゾール、1,2,4-トリアゾール(上記複素環は構成している何れかの炭素原子を介してカルボニル基に結合している)、ベンゾチアゾール、ベンゾオキサゾール、ベンゾイミダゾール、チアゾロ[5,4-b]ピリジン、オキサゾロ[4,5-b]ピリジン、イミダゾ[4,5-b]ピリジン(上記複素環は2位の炭素原子を介してカルボニル基に結合している)を示し、R<sup>1</sup>はグアニジノ基、アミジノチオ基、アミジノ基、アミノ基、水酸基、メルカプト基、低級アルコキシ基、もしくはグアニジノ基、アミジノ基、アミノ基、水酸基、メルカプト基、ハロゲンで置換されてもよいフェニル基を示し、Bは以下の式から選択される残基

【化3】

基、チエニル基、ビリル基、インドリル基、ナフチル基、ジフェニルメチル基、シクロベンチル基、シクロヘ

キシル基、フェニルチオ基、Xと結合しているメチレンを示し、Xは水素原子、水酸基、アミノ基、ハロゲン原子、炭素数1~4のアルキルアミノ基、アシルアミノ基、アルコキシカルボニルアミノ基、アリールオキシカルボニルアミノ基を示し、mは1~5の整数を示し、nは0~4の整数を示す複素環カルボニル化合物。

【請求項3】請求項1または請求項2に記載の複素環カルボニル化合物または薬理的に許容されるそれらの塩を有効成分として含有するトロンビン阻害剤。

【発明の詳細な説明】

【0001】

【産業上の利用分野】本発明はトロンビン阻害作用を有する新規な複素環カルボニル化合物に関する。


【0002】

【従来の技術】トロンビン阻害作用を示す化合物としては、例えば特開昭54-100342、米国特許第4399065号、4927809号等に記載のものが知られている。しかしながらこれら従来の化合物はトロンビン阻害活性が十分ではなく、より高い活性と酵素選択性を有する化合物が求められているといえる。

【発明の概要】

【0003】

【発明が解決しようとする課題】本発明者はプロテアーゼ阻害剤の研究からトロンビン阻害作用を有する一群の新規化合物を見いだした。従って本発明はトロンビン阻害作用を有する新規な複素環カルボニル化合物を提供することを目的としている。また本発明はトロンビン阻害作用を有する新規な複素環カルボニル化合物を有効成分として含有するトロンビン阻害剤の提供をその目的\*



(R<sup>3</sup>は一般式(I)で定義したものと同じ意味を表す)を示し、R<sup>2</sup>は置換されてもよいフェニル基、チエニル基、ピリジル基、インドリル基、ナフチル基、ジフェニルメチル基、シクロペンチル基、シクロヘキシル基、フェニルチオ基、Xと結合しているメチレンを示し、Xは水素、水酸基、アミノ基、炭素数1~4のアルキルアミノ基、アシルアミノ基、アリールオキシカルボニルアミノ基、アルコキシカルボニルアミノ基を示し、mは1~5の整数を示し、nは0~4の整数を示す。]

また本発明によるトロンビン阻害剤および抗凝固剤は前


\*としている。

【0004】

【課題を解決するための手段】本発明による複素環カルボニル化合物は下記の一般式(1)で表される化合物およびその薬理的に許容される塩である。

【0005】

【化4】



10

20

【式中、Aは少なくとも1個窒素原子を有する5員環もしくは6員環の飽和、部分飽和または不飽和である単環式複素環、またはベンゼン環もしくはピリジン環が縮合している二環式複素環(上記複素環は酸素原子、イオウ原子または別途3個以下の窒素原子を有してもよく、単環式複素環では環内の炭素原子または双環式複素環ではベンゼン環もしくはピリジン環の炭素原子に炭素数1~4の低級アルキル基、ハロゲン、水酸基、アミノ基、メルカプト基で置換してもよく、また複素環を構成している何れかの炭素原子を介してカルボニル基に結合している)を示し、R<sup>1</sup>は炭素数1~6の分岐してもよいアルキル基、グアニジノ基、アミジノチオ基、アミジノ基、アミノ基、水酸基、メルカプト基、低級アルコキシ基、もしくはグアニジノ基、アミジノ基、アミノ基、水酸基、メルカプト基、ハロゲン原子で置換されてもよいフェニル基を示し、Bは以下から選択される残基

【0006】


【化5】

記一般式(1)の化合物と薬理上許容される塩を含んでもよいものである。本発明による上記一般式(1)の化合物は強いトロンビン阻害活性を有し、医薬として有用である。

【0007】【発明の具体的説明】一般式(i)においてAが表す置換基としては1個の窒素原子を有する5員環もしくは6員環の飽和、部分飽和である単環式複素環、またはベンゼン環もしくはピリジン環が縮合している二環式複素環(上記複素環は酸素原子、イオウ原子または別途3個以下の窒素原子を有してもよく、単環式複

5

素環では環内の炭素原子または二環式複素環ではベンゼン環もしくはピリジン環の炭素原子に炭素数1~4の低級アルキル基、ハロゲン、水酸基、アミノ基、メルカプト基で置換してもよく、また複素環を構成している何れかの炭素原子を介してカルボニル基に結合している)である。好ましくはチアゾール、オキサゾール、イミダゾール、チアゾリン、オキサゾリン、イミダゾリン、ピリジン、ピリミジン、ピラゾール、1,2,4-チアジアゾール、1,2,4-オキサジアゾール、1,2,4-トリアゾール(上記複素環は構成している何れかの炭素原子を介してカルボニル基に結合している)等の単環式複素環、もしくはベンゾチアゾール、ベンゾオキサゾール、ベンゾイミダゾール、チアゾロ[5,4-b]ピリジン、オキサゾロ[4,5-b]ピリジン、イミダゾ[4,5-b]ピリジン(上記複素環は2位の炭素原子を介してカルボニル基に結合している)等の二環式複素環である。



(R<sup>2</sup>は一般式(I)で定義したものと同じ意味を表す)

【0011】また一般式(I)においてR<sup>2</sup>が表す置換基としては分岐してもよいアルキル基、アリール基、置換してもよいフェニル基、シクロアルキル基、窒素原子を1または2個含む複素飽和(芳香)環、酸素原子または硫黄原子を一個含む5または6員の複素飽和(芳香)環であり、Xと結合しているメチレンであり、nは0~5の整数である。好ましくはR<sup>2</sup>がフェニル基、ジフェニルメチル基、ビフェニル基、ナフチル基、ピリジル基、ピロール基、インドリル基、チエニル基、フラニル基、フェニルチオ基、Xと結合しているメチレンで形成される複素環としてはピロリジン、ピペリジンであり、nは0~2の整数である。

【0012】また一般式(I)においてXが表す置換基としては水素、ハロゲン、水酸基、アミノ基、アルキルアミノ基、アシルアミノ基、アルコキシカルボニルアミノ基である。好ましくはアミノ基、メチルアミノ基、アセチルアミノ基、フェニルアセチルアミノ基、ベンジルオキシカルボニルアミノ基、t-ブトキシカルボニルアミノ基等が挙げられる。

【0013】本発明の好ましい化合物群としては、一般式(I)において、Aがチアゾール、R<sup>1</sup>がグアニジノ基、Bが次の構造式から選択される残基であり、

6

\*【0008】また一般式(I)においてR<sup>1</sup>が表す置換基としてはメチル基、イソプロピル基、グアニジノ基、アミジノチオ基、アミジノ基、アミノ基、水酸基、メルカプト基、低級アルコキシ基、或はグアニジノ基、アミジノ基、アミノ基、水酸基、メルカプト基、ハロゲン原子で置換されてもよいフェニル基であり、mは1~5の整数である。好ましくはR<sup>1</sup>はグアニジノ基、アミジノ基、アミノ基、もしくはグアニジノ基、アミジノ基、アミノ基で置換されたフェニル基であり、mは3~5の整数である。


【0009】また一般式(I)においてBが表す残基としてはα-アミノ酸、イミノ酸残基あるいは直鎖状または環状カルボニル化合物である。好ましくは下記構造式から選択される残基があげられる。

【0010】

【化6】

【0014】


【化7】



(R<sup>2</sup>は一般式(I)で定義したものと同じ意味を表す)、R<sup>2</sup>がアリール基、シクロアルキル基もしくはフェニルチオ基、Xが水素、アミノ基もしくはベンジルオキシカルボニルアミノ基、mが3、nが0もしくは1である化合物、Aがチアゾール、R<sup>1</sup>がアミノ基、Bが次の構造式から選択される残基であり、

【0015】

【化8】



(R<sup>3</sup>は一般式(I)で定義したものと同意味を表す)、  
R<sup>2</sup>がアリール基、シクロアルキル基もしくはフェニル  
チオ基、Xが水素、アミノ基もしくはベンジルオキシカル  
ボニルアミノ基、mが4もしくは5、nが0もしくは1  
である化合物が挙げられる。


【0016】さらに、本発明の好ましい具体的化合物と  
しては、例えば、D-フェニルアラニル-N-[1-[(2-チアゾ  
リル)カルボニル]-4-グアニジノブチル]-L-プロリンア  
ミド、D-シクロヘキシルアラニル-N-[1-[(2-チアゾ  
リル)カルボニル]-4-グアニジノブチル]-L-プロリンアミ  
ド、D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボ  
ニル]-4-グアニジノブチル]-L-オクタヒドロインドール  
-2-カルボキシアミド、D-フェニルグリシル-N-[1-[(2-  
チアゾリル)カルボニル]-4-グアニジノブチル]-L-プロ  
リンアミド、(ベンジルオキシカルボニル)-D-フェニル  
アラニル-N-[1-[(2-チアゾリル)カルボニル]-4-グアニ  
ジノブチル]-L-プロリンアミド、アセチル-D-フェニル  
アラニル-N-[1-[(2-チアゾリル)カルボニル]-4-グアニ  
ジノブチル]-L-プロリンアミド、フェニルプロピオン  
-N-[1-[(2-チアゾリル)カルボニル]-4-グアニジノブチ  
ル]-L-プロリンアミド、2-[N-[2-(フェニルチオアセチ  
ル)シクロペンタ-1-イルカルボニル]-L-アルギニル]チ  
アゾール、D-フェニルアラニル-N-[1-[(2-チアゾリル)  
カルボニル]-5-アミノペンチル]-L-プロリンアミド、D-  
フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]-6  
-アミノヘキシル]-L-プロリンアミドなどが挙げられ  
る。

【0017】本発明による化合物は分子中の炭素原子に  
由来する立体異性体が存在し得るが、いずれの異性体も  
本発明に包含されるものである。本発明による化合物は  
その塩とすることができる。そのような塩としては、  
薬理学的に許容される塩が挙げられ、好ましくは塩化水素  
酸、臭化水素酸、ヨウ化水素酸、硝酸、硫酸、リン酸、  
酢酸、クエン酸、マレイン酸、コハク酸、乳酸、酒石  
酸、メタンスルホン酸、エタンスルホン酸、ベンゼンス  
ルホン酸、p-トルエンスルホン酸等が挙げられる。

【0018】一般式(I)の化合物は種々の方法で合成  
することができる。例えば、次の一般式(II)

【0019】


【化9】



(ここで、R<sup>2</sup>、X、B、nは一般式(I)で定義したも  
のとおなじ意味を表す、かつXは保護基を有する基を表  
す)で表される化合物と、次の一般式(III)

【0020】


【化10】



(ここで、R<sup>1</sup>、A、mは一般式(I)で定義したもの  
のとおなじ意味を表す、かつR<sup>1</sup>は保護基を有する基を表  
す。)で表される化合物とを、適当なカップリング試薬  
と反応することによって次の一般式(IV)

【0021】

【化11】



(ここで、R<sup>1</sup>、R<sup>2</sup>、A、B、X、m、nは前記で定義  
したものと同意味を表す)の化合物を得ることがで  
きる。合成上、R<sup>1</sup>およびXに保護基を必要とする場  
合には一般的にペプチド化学で用いられる保護基を用い  
ることができる。好ましくはL-プトキシカルボニル  
基、ベンジルオキシカルボニル基、4-メトキシ-2,3,6-  
トリメチルベンゼンスルホニル基等を挙げることができ  
る。

【0022】カップリング試薬はペプチド化学で用いら  
れる試薬を使用することができる。好ましいカップリン  
グ試薬は例えば、N'-ジシクロヘキシルカルボジイミ  
ド、1-エチル-3-(3'-ジメチルアミノプロピル)カル  
ボジイミド、ベンゾトリアゾール-1-イルオキシトリ  
ス(ジメチルアミノ)ホスホニウムヘキサフルオロホス  
フェート、N,N'-ビス[2-オキソ-3-オキサソリジニ  
ル]ホスホロジアミドクロライド、ジフェニルホスフ  
イニルクロライドである。これらの試薬存在下に、適  
当な溶媒(例えば、酢酸エチル、アセトニトリル、塩化  
メチレン、DMF)中で、-70〜30℃、好ましくは-20  
〜10℃で反応を行うことができる。

【0023】次いで化合物(IV)の水酸基を酸化してケ  
トンとし、必要によって保護基を除去し、一般式(I)  
の複素環カルボニル化合物を得ることができる。酸化  
反応はシンセシス(Synthesis)1990年、857頁に  
記載のように種々の添加物を用いたジメチルスルホキシ

9

ドにより行うことができる。またテトラ-*n*-プロピルアンモニウム、パールテナイト、ピリジニウム、ジクロメイト、ピリジニウムクロクロメイトによっても酸化することができる。好ましくはオキザリルクロライドの存在下ジメチルスルホキシドによる酸化であり、例えば塩化メチレンを溶媒として-70~0℃でオキザリルクロライドとジメチルスルホキシドから調製した試薬と化合物(IV)とを反応させ、次いでトリエチルアミンで処理することによって一般式(I)の化合物を得ることができる。


【0024】一般式(I)の化合物を得るために、脱保護反応を必要とする場合には種々な反応条件が選択される。例えば前述の保護基が用いられた場合にはパラジウム炭素を触媒とする水素化分解もしくはアニソール、チオアニソール存在下トリフルオロ酢酸を作用させる酸分解反応で脱保護が行われる。

【0025】本発明の一般式(I)の化合物は種々の無機酸または有機酸と酸付加塩を形成する。上記反応で得られる化合物(I)は遊離の形態または塩の形態で単離され、遊離の形態の場合には所望の酸と反応させることにより酸付加塩を得ることができる。

【0026】出発物質である上記アミン化合物(III)を得るためにはケミカルレビュー(Chemical Review)1989年、89巻、149頁に記載の方法で得られるアミノアルデヒド化合物(V)

【0027】

【化12】



(R<sup>1</sup>, mは一般式(II)で定義したものとおなじ意味を、Allocはアリロキシカルボニル基を表す)を、ジャーナル・オブ・ヘテロサイクリック・ケミストリー(Journal of Heterocyclic Chemistry)1971年、8巻、257頁、ジャーナル・オブ・オーガニック・ケミストリー(Journal of Organic Chemistry)1988年、53巻、1748頁等に記載のシリル化合物(VIa)

【0028】


【化13】



(Aは一般式(I)で定義したものとおなじ意味を表す)と反応させカルビノール化合物(VII)

【0029】

【化14】



10

を得ることができる。好ましくはこの反応は塩化メチレンを溶媒としてフッ化セシウム、テトラブチルアンモニウムフルオライドの存在下もしくは非存在下0~50℃の温度で反応を行うことができる。もしくは出発物質である複素環化合物(B-A)を不活性溶媒(例えばテトラヒドロフラン、ジメトキシエタン)中、*n*-ブチルリチウム等の塩基で処理し、化合物(VIb)

【0030】

【化15】




として、次いで上記化合物(V)と反応させ化合物(VI)を得ることができる。化合物(VII)のアミノ基保護基を公知の方法である、例えばPd(Ph<sub>3</sub>P)<sub>4</sub>存在下、ピロリジンで処理し除去することにより上記アミン化合物(III)を得ることができる。

【0031】また出発物質である上記カルボン酸化合物(II)はB-OHがアミノ酸残基の場合にはペプチド化学の一般的方法で得ることができる。カルボン酸化合物(VI)を反応性誘導体(例えば酸ハライド、酸無水物、活性エステル)に導き、アミノ酸(IX)のアルカリ金属塩もしくは有機塩基との塩と反応させることにより化合物(I)を得ることができる。好ましくは化合物(VIII)をN-ヒドロキシコハク酸イミドと反応させ活性エステルに変換し、それを有機塩基の存在下にアミノ酸(IX)と反応させてペプチド結合を形成することによって行われる。

【0032】

【化16】



また上記化合物(II)のB-OHが脂肪酸カルボン酸の場合には環状または直鎖状ジカルボン酸から得ることができる。例えば環状ジカルボン酸では、そのモノアルキルエステル(1)をチオニルクロライドもしくはオキザリルクロライドと反応させ酸クロライド(2a)とし、これをジアゾメタンで処理してジアゾメチルケトン(2b)に変換する。このケトンを無水塩化水素と反応させクロメルケトン(2c)とし、次いでチオフェノールで処理することによってフェニルチオメルケトン(3)に変換する。


この化合物のエステルを加水分解し、カルボン酸化合物(II)を得ることができる。

【0033】

【化17】

11

12



(R'はメチル基、ベンジル基、ジフェニルメチル基を表す)

【0034】本発明の化合物(I)およびその酸付加塩はトロンビンに対して選択性の高い阻害作用を示すことから血中のトロンビンを測定する診断薬、血小板凝集阻

【0035】本発明による一般式(I)で表される化合物およびその薬理学的に許容される塩を有効成分として含有するトロンビン阻害剤は、経口または非経口投与(例えば、吸入投与、点鼻、点眼、皮下投与、静注、筋注など)に適した種々の剤形で使用される。

【0036】例えば、その用途に応じて、錠剤、カプセル剤、顆粒剤、散剤、細粒剤、トローチ剤、シロップ剤、乳濁剤などの経口剤、吸入剤、点鼻剤、点眼剤などの外用液剤、静注および筋注などの注射剤などの製剤形態に調製することができる。これらの各種製剤は、通常用いられている賦形剤、増量剤、結合剤、湿潤化剤、崩壊剤、潤滑剤、分散剤、緩衝剤、保存剤、溶解補助剤、防腐剤、安定化剤などを用いて常法により製造することができる。

【0037】薬剤中における本発明の化合物の含有量は、その剤形に応じて異なるが、通常全組成物中1~70重量%、好ましくは5~50重量%である。またその投与量は用法、患者の年齢、性別、症状の程度などを考慮し\*

$$\text{阻害率}(\%) = \frac{[(a_2 - b) - (a_1 - b)]}{(a_2 - b)} \times 100$$

本発明の代表的化合物についてこの試験結果を表1に示す。

表1 トロンビン阻害活性

化合物の実施例番号	50%阻害濃度 IC <sub>50</sub> (μM/ml)
1	0.0015
2	0.16
4	0.012
5	0.32
7	0.007
8	0.002
アルガトロバン*	0.065

\*適宜決定されるが、通常成人1日当たり約0.1~2000mg、好ましくは5~400mg程度とするのがよく、これを1日1回または数回に分けて投与することができる。

【0038】in vitro 阻害活性の測定方法

in vitro の系におけるトロンビン阻害活性はヨーロッパ・ジャーナル・オブ・バイオケミストリー(European Journal of Biochemistry)1988年、172巻、17頁に記載の方法により求めた。0.1Mトリス塩酸緩衝液(pH 8.0; 0.3 M NaClおよび2 mM CaCl<sub>2</sub>を含有)100 ml、本発明化合物のDMSO溶液 10 ml、牛血清アルブミン溶液(0.4 mg/ml) 50 mlおよび上記トリス塩酸緩衝液に溶解したトロンビン(0.5 U/ml) 20 mlの混合液を調製した。これに基質である5 mM Boc-Asp(OBzl)-Pro-Arg-メチルカルマリンアミド溶液(10% DMSO) 20 mlを加え、37℃で30分間インキュベートしたのち、380nmのUVで励起された440 nmの蛍光強度(a<sub>1</sub>)を測定した。同時に、本発明化合物溶液をDMSOに代えた実験を行い、同様に蛍光強度(a<sub>2</sub>)を測定した。またバックグラウンドとして上記0.1Mトリス塩酸緩衝液 120 ml、DMSO溶液 10 ml、牛血清アルブミン溶液 50 mlおよび基質溶液 20mlの混合液の蛍光強度(b)を測定した。阻害率を次式より計算し、50%阻害に必要な濃度(IC<sub>50</sub>)を求めた。

## \*特公昭61-48829記載の化合物

[0039]

【実施例】本発明の化合物について以下に実施例を挙げ、詳しく説明するが、これらは単なる例示であってなんら本発明を限定するものではない。

## [0040] 実施例1

D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]-4-グアニジノブチル]-L-プロリンアミド

(a) L-プトキシカルボニル-D-フェニルアラニル-N-[1-[(2-チアゾリル)ヒドロキシメチル]-4-[[N', N''-ビス(L-プトキシカルボニル)アミノイミノメチル]アミノ]ブチル]-L-プロリンアミド

L-プトキシカルボニル-D-フェニルアラニル-L-プロリン(300 mg, 0.82 mmol)、2-[2-アミノ-5-[N', N''-ビス(L-プトキシカルボニル)アミノイミノメチル]アミノ-1-ヒドロキシベンチル]チアゾール(367 mg, 0.82 mmol)、N-ヒドロキシベンゾトリアゾール(110 mg, 0.82 mmol)をアセトニトリル15 mlに溶解し、氷冷下1-エチル-3-(3'-ジメチルアミノプロピル)カルボジイミド塩酸塩(187 mg, 0.98 mmol)を加え、同温度で3時間、室温まで昇温して15時間攪拌した。反応混合物を濃縮した後に酢酸エチルに溶解し、水洗後、MgSO<sub>4</sub>で乾燥した。溶液を留去し、粗生成物をフラッシュクロマトグラフィーで精製して標記化合物(497 mg, 77 %)を得た。

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.42-1.62 (m, 32H), 1.79-1.89 (m, 2H), 2.47-2.50 (m, 1H), 2.93-3.00 (m, 2H), 3.33-3.43 (m, 4H), 4.01-4.04 (m, 1H), 4.25-4.29 (m, 1H), 4.43-4.60 (m, 1H), 4.98-5.02 (m, 1H), 5.47-5.50 (m, 1H), 7.15-7.29 (m, 6H), 7.71-7.75 (m, 1H), 8.33-8.36 (m, 1H)。

[0041] (b) D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]-4-グアニジノブチル]-L-プロリンアミド

オキザリルクロライド(79 ml, 0.91 mmol)を塩化メチレン8 mlに溶解し、-40℃でジメチルスルホキシド(129 ml, 0.91 mmol)を加え、5分間攪拌した。上記化合物(480 mg, 0.61 mmol)を含む塩化メチレン溶液5 mlを加え、-40~-30℃で30分間攪拌した。次いでトリエチルアミン(581 ml, 4.1 mmol)を加え、同温度で30分間攪拌した後に氷水にかけた。有機層を分液し、水洗後、MgSO<sub>4</sub>で乾燥して濃縮した。生成物をフラッシュクロマトグラフィーで精製してL-プトキシカルボニル-D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]-4-[N', N''-ビス(L-プトキシカルボニル)アミノイミノメチル]アミノ]ブチル]-L-プロリンアミド(407 mg, 85 %)を得た。この化合物をアニソール1 mlに溶解し、氷冷下トリフルオロ酢酸4 mlを加え、同温度で30分間、室温で30分間攪拌した。反応混合物を濃縮し、水5 mlに溶解し、エーテルで洗浄した後に凍結乾燥を行い標記化合物(407 mg)を得た。<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.59-1.60 (m, 1

H), 1.70-1.91 (m, 5 H), 2.12-2.14 (m, 2 H), 2.75-2.81 (m, 1 H), 3.15-3.29 (m, 4 H), 3.50-3.54 (m, 1 H), 4.43-4.46 (m, 1 H), 4.53-4.61 (m, 1 H), 5.49-5.55 (m, 1 H), 7.32-7.46 (m, 5 H), 8.11-8.15 (m, 2 H); MS (SIMS) m/z 486 (M<sup>+</sup>)。

## [0042] (c) 中間体の合成

この実施例で用いた2-[2-アミノ-5-[N', N''-ビス(L-プトキシカルボニル)アミノイミノメチル]アミノ-1-ヒドロキシベンチル]チアゾールは以下の方法で合成した。L-アルギニン(10 g, 57 mmol)を水60 mlに溶解し、4 N-NaOHでpH 9~10に保ちながら氷冷下クロルギ酸アリル(8.99 mg, 74 mmol)を加え、pH 7に調整して同温度で2時間攪拌した。析出する沈澱物を濾取し、少量の氷水とアセトンで洗浄し、乾燥してN-アリルオキシカルボニル-L-アルギニン(13.3 g, 90 %)を得た。上記化合物(10 g, 39 mmol)とp-トルエンスルホン酸(7 g, 37 mmol)をメタノール250 mlに溶解し、ジフェニルジアゾメタン(15 g, 78 mmol)を1時間かけて加え、室温で3時間攪拌した後に濃縮した。反応生成物をクロロホルムに溶解し、水洗後、MgSO<sub>4</sub>で乾燥して濃縮し、N-アリルオキシカルボニル-L-アルギニンジフェニルメチルエステルp-トルエンスルホン酸塩(24 g)を得た。上記粗生成物(24 g)をアセトニトリル250 mlに溶解し、ジメチルアミノピリジン(4.7 g, 39 mmol)、ビス-L-プチルジカルボネート(21 g, 97 mmol)を加え、室温で15時間攪拌した後に濃縮した。反応混合物を酢酸エチルに溶解し、水洗後、MgSO<sub>4</sub>で乾燥して濃縮し、シリカゲルクロマトグラフィー(n-ヘキサン/酢酸エチル)で精製しNα-アリルオキシカルボニル-N', N''-ビス(L-プトキシカルボニル)-L-アルギニンジフェニルメチルエステル(14.5 g, 60 %)を得た。

[0043] 上記化合物(11 g, 18 mmol)をテトラヒドロフラン150 mlに溶解し、LiBH<sub>4</sub>(0.75g, 35 mmol)を加え室温で2時間攪拌する。反応混合物をpH 3の酸性水にあげ、酢酸エチルで抽出し、有機層を水洗後、MgSO<sub>4</sub>で乾燥して濃縮した。反応生成物をシリカゲルクロマトグラフィー(n-ヘキサン/酢酸エチル)で精製しNα-アリルオキシカルボニル-N', N''-ビス(L-プトキシカルボニル)-L-アルギニン(3.9 g, 50 %)を得た。

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.35-1.80 (m, 22H), 3.30-3.80 (m, 6H), 4.58 (d, J = 5.02 Hz, 1H), 5.22 (dd, J = 1.55, 10.0 Hz, 1H), 5.31 (dd, J = 1.55, 17.6 Hz, 1H), 5.49 (d, J = 7.53 Hz, 1H), 5.93 (ddd, J = 5.02, 10.0, 17.6 Hz, 1H), 8.38 (t, J = 5.02 Hz, 1H)。オキザリルクロライド(1.27 g, 10 mmol)を塩化メチレン40 mlに溶解し、-30℃でジメチルスルホキシド(1.57 g, 20 mmol)を加え5分後に上記カルビノール化合物(3.0 g, 6.7 mmol)を含む塩化メチレン溶液 20 mlを加え-30℃で30分間攪拌した。次いでトリエチルアミン(4.62 g, 45 mmol)

1)を加えて-30℃で30分間攪拌した後、氷水にあげて分液する。有機層を水洗後、MgSO<sub>4</sub>で乾燥して濃縮し、N-α-アリルオキシカルボニル-N',N''-ビス(1-ブトキシカルボニル)-L-アルギニナル(2.9 g)を得た。

【0044】上記粗生成物(2.9 g)と2-トリメチルシリルチアゾール(1.54 mg, 9.8 mmol)を塩化メチレン50 mlに溶解し、室温で5時間攪拌する。1M テトラ-n-ブチルアンモニウムフルオリドTHF溶液(10.4 ml)を加え、さらに30分間攪拌し、氷水にあげる。有機層を分液しMgSO<sub>4</sub>で乾燥して濃縮した。シリカゲルクロマトグラフィー(n-ヘキサン/酢酸エチル)で精製し2-[2-(α-アリルオキシカルボニルアミノ-5-[N',N''-ビス(1-ブトキシカルボニル)アミノイミノメチル]アミノ-1-ヒドロキシベンチル)チアゾール(2.1 g, 60%)を得た。

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.35-1.86 (m, 22H), 3.30-3.55 (m, 2H), 4.05-4.22 (m, 1H), 4.43-4.65 (m, 2H), 5.06-5.40 (m, 4H), 5.78-6.02 (m, 2H), 7.28 (d, J=3.0 Hz, 1H), 7.73 (d, J=3.0 Hz, 1H), 8.48 (t, J=6.24 Hz, 1H)。

【0045】上記化合物(2.1 g)を塩化メチレン35 mlに溶解し、ピペリジン(1.34 g, 19 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub>(220 mg, 0.19 mmol)を加え、室温で30分間攪拌する。反応混合物を濃縮し、シリカゲルクロマトグラフィー(クロロホルム/メタノール)で精製し標記化合物(1.4 g, 85%)を得た。

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.40-1.80 (m, 22H), 3.17-3.55 (m, 4.70-4.80 (m, 1H), 4.88-4.98 (m, 1H), 7.40-7.80 (m, 3H), 8.30-8.43 (m, 1H)。

#### 【0046】実施例2

2-[2-(フェニルチオアセチル)シクロペンタ-1-イルカルボニル]-L-アルギニルチアゾール

(a) 2-[2-(フェニルチオアセチル)シクロペンタ-1-イルカルボニル]アミノ-5-[N',N''-ビス(1-ブトキシカルボニル)アミノイミノメチル]アミノ-1-ヒドロキシベンチル]チアゾール

2-(フェニルチオアセチル)シクロペンタンカルボン酸(249 mg, 0.94 mmol)、2-[2-アミノ-5-[N',N''-ビス(1-ブトキシカルボニル)アミノイミノメチル]アミノ-1-ヒドロキシベンチル]チアゾール(417 mg, 0.94 mmol)、N-ヒドロキシベンゾトリアゾール(126 mg, 0.94 mmol)をアセトニトリル20 mlに溶解し、氷冷下1-エチル-3-(3'-ジメチルアミノプロピル)カルボジイミド塩酸塩(215 mg, 0.98 mmol)を加え、同温度で3時間、室温まで昇温して15時間攪拌した。反応混合物を濃縮した後に酢酸エチルに溶解し、水洗後、MgSO<sub>4</sub>で乾燥した。溶媒を留去し、粗生成物をフラッシュクロマトグラフィーで精製して標記化合物(438 mg, 68%)を得た。

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.20-2.10 (m, 28H), 2.87 (m, 1H), 3.30-3.50 (m, 3H), 3.24 (m, 1H), 4.25 (m, 1H), 5.03 (m, 1H), 6.75 (m, 1H), 7.15-7.40 (m, 5H), 7.43-

7.57 (m, 1H), 7.70 (m, 1H), 8.37 (m, 1H)。

【0047】(b) 2-[2-(フェニルチオアセチル)シクロペンタ-1-イルカルボニル-L-アルギニル]チアゾールオキサリルクロライド(81 ml, 0.93 mmol)を塩化メチレン10 mlに溶解し、-40℃でジメチルスルホキシド(132 ml, 1.87 mmol)を加え、5分間攪拌した。上記化合物(430 mg, 0.62 mmol)を含む塩化メチレン溶液5 mlを加え、-40~-30℃で30分間攪拌した。次いでトリエチルアミン(596 ml, 4.2 mmol)を加え、同温度で30分間攪拌した後に氷水にあげた。有機層を分液し、水洗後、MgSO<sub>4</sub>で乾燥して濃縮した。生成物をフラッシュクロマトグラフィーで精製して2-[2-(フェニルチオアセチル)シクロペンタ-1-イルカルボニル-N',N''-ビス(1-ブトキシカルボニル)アルギニル]チアゾール(350 mg, 83%)を得た。この化合物をアニソール1 mlに溶解し、氷冷下トリフルオロ酢酸4 mlを加え、同温度で30分間、室温で30分間攪拌した。反応混合物を濃縮し、フラッシュクロマトグラフィー(クロロホルム/メタノール)で精製し標記化合物(254 mg)を得た。

<sup>1</sup>H-NMR(CD<sub>3</sub>OD) δ 1.60-2.20 (m, 10H), 3.05 (m, 1H), 3.24 (m, 2H), 3.53 (m, 1H), 3.90 (m, 2H), 5.56 (m, 1H), 7.10-7.40 (m, 5H), 8.05 (m, 1H), 8.12 (m, 1H); MS(M<sup>+</sup>) m/z 488 (M<sup>+</sup>)。

#### 【0048】(c)中間体の合成

この実施例で用いた2-フェニルチオメチルカルボニルシクロペンタ-1-カルボン酸は以下の方法で合成した。2-[(ジフェニル)メトキシカルボニル]シクロヘキサン-1-カルボン酸(2.0 g, 6.17 mmol)、トリエチルアミン(0.944 ml, 6.79 mmol)を塩化メチレン20 mlに溶解し、氷冷下、N,N-ジメチルホルムアミド(1滴)、オキサリルクロライド(855 mg, 6.79 mmol)を加え、1時間攪拌した。次いで氷冷下、過剰のジアゾメタンを含むエーテル溶液を加え30分間攪拌し、4N-HClジオキサン溶液(2.31 ml)を加え更に30分間攪拌した。反応混合物を濃縮し、生成したクロルメチルケトンにテトラヒドロフラン30 mlに溶解し、ジイソプロピルエチルアミン(815 mg, 6.32 mmol)、チオフェノール(690 mg, 6.32 mmol)を加え、室温で3時間攪拌した後に濃縮した。反応生成物をシリカゲルクロマトグラフィー(トルエン/酢酸エチル)で精製してフェニルチオメチルケトン(2.12 g, 86%)を得た。この生成物をメタノール200 mlに溶解し、1M 炭酸カリウム水溶液(9.74 ml)を加えて室温で15時間攪拌した。反応混合物を濃縮し、残留物を水に溶解し、エーテルで洗浄した。水層を酸性とした後に酢酸エチルで抽出し、MgSO<sub>4</sub>で乾燥し、濃縮して標記化合物(0.97 g, 76%)を得た。

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.60-2.10 (m, 6H), 3.20 (m, 1H), 3.58 (m, 1H), 3.80 (s, 2H), 7.15-7.40 (m, 5H)。

#### 【0049】実施例3

D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]



-5-アミノベンチル]-L-プロリンアミド

(a) t-ブトキシカルボニル-D-フェニルアラニル-N-[1-[(2-チアゾリル)ヒドロキシメチル]-5-(ベンジルオキシカルボニル)ベンチル]-L-プロリンアミド-t-ブトキシカルボニル-D-フェニルアラニル-L-プロリン(255 mg, 0.70 mmol)、2-[2-アミノ-6-(ベンジルオキシカルボニル)アミノ-1-ヒドロキシヘキシル]チアゾール(245 mg, 0.70 mmol)、N-ヒドロキシベンゾトリアゾール(94 mg, 0.70 mmol)をアセトニトリル15 mlに溶解し、氷冷下1-エチル-3-(3'-ジメチルアミノプロピル)カルボジミド塩塩(160 mg, 0.84 mmol)を加え、同温度で3時間、室温まで昇温して15時間攪拌した。反応混合物を濃縮した後に酢酸エチルに溶解し、水洗後、MgSO<sub>4</sub>で乾燥した。溶媒を留去し、粗生成物をフラッシュクロマトグラフィー(酢酸エチル)で精製して標記化合物(393 mg, 81%)を得た。

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.20-2.15 (m, 20H), 2.40-2.80 (m, 1H), 2.90-3.47 (m, 3H), 3.65-3.77 (m, 1H), 4.23-4.58 (m, 3H), 4.95-5.04 (m, 2H), 5.04-5.30 (m, 2H), 5.30-5.56 (m, 2H), 7.04-7.90 (m, 12H)。

[0050] (b) D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]-5-アミノベンチル]-L-プロリンアミド  
 オキザリルクロライド(72 ml, 0.84 mmol)を塩化メチレン8 mlに溶解し、-40℃でジメチルスルホキシド(119 ml, 1.68 mmol)を加え、5分間攪拌した。上記化合物(390 mg, 0.56 mmol)を含む塩化メチレン溶液5 mlを加え、-40~-30℃で30分間攪拌した。次いでトリエチルアミン(394 ml, 2.81 mmol)を加え、同温度で30分間攪拌した後に氷水にかけた。有機層を分液し、水洗後、MgSO<sub>4</sub>で乾燥して濃縮した。生成物をフラッシュクロマトグラフィー(ヘキサン/酢酸エチル)で精製してt-ブトキシカルボニル-D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]-5-(ベンジルオキシカルボニル)アミノベンチル]-L-プロリンアミド(388 mg, 73%)を得た。この化合物を辛酸(3.5 ml)に溶解し、Pd(150 mg)を加え室温で3時間攪拌した。反応混合物を濾過した後に濾液を濃縮し、生成物をアニソール1 mlに溶解し、氷冷下トリフルオロ酢酸(3 ml)を加え、同温度で30分間攪拌した。反応混合物を濃縮し、水5 mlに溶解し、エーテルで洗浄した後に凍結乾燥を行い標記化合物(190 mg)を得た。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.25-2.04 (m, 7H), 2.04-2.18 (m, 1H), 2.64-2.82 (m, 2H), 3.00-3.70 (m, 6H), 4.30-4.45 (m, 2H), 5.45-5.55 (dd, J = 4.14, 9.31 Hz, 1H), 7.20-7.55 (m, 5H), 7.70-8.20 (m, 2H); MS(FD) m/z 458 (M<sup>+</sup>)。

[0051] (c) 中間体の合成

この実施例で用いた2-[2-アミノ-6-(ベンジルオキシカルボニル)アミノ-1-ヒドロキシヘキシル]チアゾールはN

α-アリルオキシカルボニル-Nω-ベンジルオキシカルボニル-L-リジンメチルエステルを出発物質として用い実施例1cと同様な方法で合成した。

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.20-1.80 (m, 6H), 1.80-1.95 (m, 1H), 3.10-3.34 (m, 3H), 3.60-3.80 (m, 1H), 4.70 (d, J = 3.78 Hz, 1H), 4.80-4.97 (m, 1H), 5.01 (s, 2H), 7.29 (d, J = 2.52 Hz, 1H), 7.30-7.38 (m, 5H), 7.73 (d, J = 2.52 Hz, 1H)。

[0052] 実施例4

10 D-シクロヘキシルアラニル-N-[1-[(2-チアゾリル)カルボニル]-4-グアニジノブチル]-L-プロリンアミド  
 t-ブトキシカルボニル-D-シクロヘキシルアラニル-L-プロリンと実施例1cの化合物から実施例1と同様な方法で合成した。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.00-1.55 (m, 4H), 1.55-2.25 (m, 14H), 2.30-2.40 (m, 1H), 3.22-3.30 (m, 2H), 3.58-3.70 (m, 1H), 3.72-3.82 (m, 1H), 4.39 (dd, J = 3.45, 13.8 Hz, 1H), 4.56 (dd, J = 8.6 Hz, 1H), 4.80-5.80 (m, 1H), 8.10-8.23 (m, 2H); MS(SIMS) m/z 492 (M<sup>+</sup>)。

[0053] 実施例5

D-フェニルグリシル-N-[1-[(2-チアゾリル)カルボニル]-4-グアニジノブチル]-L-プロリンアミド

t-ブトキシカルボニル-D-フェニルグリシル-L-プロリンと実施例1cの化合物から実施例1と同様な方法で合成した。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.62-1.97 (m, 8H), 2.10-2.20 (m, 1H), 2.98-3.06 (m, 1H), 3.22-3.30 (m, 1H), 3.63-3.72 (m, 1H), 4.58 (dd, J = 3.40, 8.60 Hz, 1H), 5.38-5.43 (m, 1H), 5.50-5.60 (m, 1H), 7.45-7.60 (m, 5H), 8.10 (d, 1H), 8.20 (d, 1H); MS(SIMS) m/z 472 (M<sup>+</sup>)。

[0054] 実施例6

D-チロシル-N-[1-[(2-チアゾリル)カルボニル]-4-グアニジノブチル]-L-プロリンアミド

t-ブトキシカルボニル-D-チロシル-L-プロリンと実施例1cの化合物から実施例1と同様な方法で合成した。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.75-2.04 (m, 6H), 2.16-2.36 (m, 2H), 3.04-3.10 (m, 1H), 3.25-3.28 (m, 3H), 3.45-3.46 (m, 1H), 3.70-3.76 (m, 1H), 4.52-4.77 (m, 2H), 5.52-5.56 (m, 1H), 6.85-6.96 (m, 2H), 7.19-7.26 (m, 2H), 8.13-8.19 (m, 2H); MS(SIMS) m/z 504 (M<sup>+</sup>)。

[0055] 実施例7

D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]-4-グアニジノブチル]-L-オクタヒドロインドール-2-カルボキシアミド

t-ブトキシカルボニル-D-フェニルアラニル-L-オクタヒドロインドール-2-カルボン酸と実施例1cの化合物から実施例1と同様な方法で合成した。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 0.87-1.05 (m, 2H), 1.10-1.23 (m, 3

19

H), 1.36-1.49 (m, 3H), 1.58-1.82 (m, 5H), 1.91-2.03 (m, 2H), 2.85-3.00 (m, 2H), 3.15-3.20 (m, 3H), 4.20-4.25 (m, 1H), 4.34 (dd, J = 5.4, 10.3 Hz, 1H), 5.38 (dd, J = 4.0, 8.4 Hz, 1H), 7.19-7.36 (m, 5H), 7.98-8.04 (m, 2H); MS (SIMS) m/z 540 (M<sup>+</sup>).

#### 【0056】実施例8

ベンジルオキシカルボニル-D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]-4-グアニジノブチル]-L-プロリンアミド

ベンジルオキシカルボニル-D-フェニルアラニル-L-プロリンと実施例1cの化合物から実施例1と同様な方法で合成した。

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.40-2.20 (m, 7H), 2.59-2.80 (m, 1H), 2.90-3.50 (m, 5H), 3.50-3.80 (m, 1H), 4.28-4.54 (m, 1H), 4.54-4.70 (m, 1H), 5.04 (ABq, J=13.8, 39.7 Hz, 1H), 5.45-5.70 (m, 1H), 6.18-6.30 (m, 1H), 6.90-7.50 (m, 10H), 7.65 (d, J = 7.36 Hz, 1H), 7.84 (d, J = 7.36 Hz, 1H), 7.94-8.04 (m, 1H); MS(SIM S) m/z 620 (M<sup>+</sup>).

#### 【0057】実施例9

アセチル-D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]-4-グアニジノブチル]-L-プロリンアミド

アセチル-D-フェニルアラニル-L-プロリンと実施例1cの化合物から実施例1と同様な方法で合成した。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.50-2.50 (m, 11H), 2.52-2.75 (m, 2H), 2.97-3.13 (m, 2H), 3.15-3.50 (m, 2H), 3.65-3.80 (m, 1H), 4.35-4.50 (m, 1H), 5.35-5.50 (m, 1H), 7.23-7.56 (m, 5H), 8.00-8.22 (m, 2H); MS(SIMS) m/z 528 (M<sup>+</sup>).

#### 【0058】実施例10

3-フェニルプロピオン-N-[1-[(2-チアゾリル)カルボニル]-4-グアニジノブチル]-L-プロリンアミド

3-フェニルプロピオン-L-プロリンと実施例1cの化合物から実施例1と同様な方法で合成した。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.50-2.50 (m, 6H), 2.50-3.25 (m, 8H), 3.25-3.57 (m, 2H), 4.28-4.38 (m, 1H), 5.40-5.46 (m, 1H), 7.20-7.40 (m, 5H), 7.60-7.70 (m, 1H), 8.00-8.10 (m, 1H); MS(SIMS) m/z 471 (M<sup>+</sup>).

#### 【0059】実施例11

4-フェニルブタノイル-N-[1-[(2-チアゾリル)カルボニル]-4-グアニジノブチル]-L-プロリンアミド

4-フェニルブタノイル-L-プロリンと実施例1cの化合物から実施例1と同様な方法で合成した。

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.72-1.75 (m, 2H), 1.89-2.09 (m, 5H), 2.26-2.51 (m, 5H), 2.61-2.68 (m, 2H), 3.13-3.56 (m, 4H), 4.42-4.53 (m, 1H), 5.59 (brs, 1H), 7.08-7.28 (m, 5H), 7.70 (d, J = 3.1 Hz, 1H), 7.77-7.90 (m, 2H), 8.00 (d, J = 3.1 Hz, 1H); MS (SIMS) m/z = 485 (M<sup>+</sup>).

#### 【0060】実施例12

20

D-プロリン-N-[1-[(2-チアゾリル)カルボニル]-4-グアニジノブチル]-L-プロリンアミド

1-ブトキシカルボニル-D-プロリン-L-プロリンと実施例1cの化合物から実施例1と同様な方法で合成した。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.70-2.20 (m, 9H), 2.30-2.45 (m, 1H), 2.47-2.65 (m, 2H), 3.25-3.35 (m, 1H), 3.40-3.55 (m, 2H), 3.60-3.68 (m, 1H), 3.70-3.80 (m, 1H), 3.80-3.90 (m, 1H), 4.58 (dd, J = 3.40, 5.17 Hz, 1H), 4.68 (dd, J = 6.90, 7.59 Hz, 1H), 5.51 (dd, J = 5.17, 9.31 Hz, 1H), 8.12 (d, J = 3.40 Hz, 1H), 8.18 (d, J = 3.40 Hz, 1H); MS(PD) m/z 435 (M<sup>+</sup>).

#### 【0061】実施例13

2-[2-(フェニルチオアセチル)シクロヘキサ-1-イルカルボニル]-L-アルギニンチアゾール

2-(フェニルチオアセチル)シクロヘキサノカルボン酸と実施例1cの化合物から実施例2と同様な方法で合成した。

<sup>1</sup>H-NMR(CD<sub>3</sub>OD) δ 1.10-2.20 (m, 12H), 2.63 (m, 1H), 3.02 (m, 1H), 3.09-3.23 (m, 2H), 3.83-4.09 (m, 2H), 5.47-5.55 (m, 1H), 7.05-7.40 (m, 5H), 8.02 (m, 1H), 8.10 (m, 1H); MS(SIMS) m/z 502 (M<sup>+</sup>).

#### 【0062】実施例14

4-フェニルブタノイル-N-[1-[(2-チアゾリル)カルボニル]-5-アミノベンチル]-L-プロリンアミド

4-フェニルブタノイル-L-プロリンと実施例3cの化合物から実施例3と同様な方法で合成した。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.40-2.25 (m, 10H), 2.35 (m, 2H), 2.65 (m, 2H), 2.99 (m, 2H), 3.42-3.52 (m, 4H), 4.40 (m, 1H), 5.46 (m, 1H), 7.10-7.40 (m, 5H), 8.05 (m, 1H), 8.11 (m, 1H); MS(SIMS) m/z 457 (M<sup>+</sup>).

#### 【0063】実施例15

3-フェニルプロピオン-N-[1-[(2-チアゾリル)カルボニル]-5-アミノベンチル]-L-プロリンアミド

3-フェニルプロピオン-L-プロリンと実施例3cの化合物から実施例3と同様な方法で合成した。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.20-1.90 (m, 7H), 1.90-2.20 (m, 2H), 2.50-3.00 (m, 5H), 3.20-3.54 (m, 2H), 4.29-4.37 (m, 1H), 5.39 (dd, J = 3.75, 8.00 Hz, 1H), 7.12-7.35 (m, 5H), 7.98 (d, J = 2.77 Hz, 1H), 8.06 (d, J = 2.77 Hz, 1H); MS(SIMS) m/z 443 (M<sup>+</sup>).

#### 【0064】実施例16

D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]-6-アミノヘキシル]-L-プロリンアミド

1-ブトキシカルボニル-D-フェニルアラニル-L-プロリンと2-[2-アミノ-7-(ベンジルオキシカルボニル)アミノ-1-ヒドロキシヘプチル]チアゾールから実施例3と同様な方法で合成した。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.20-1.90 (m, 9H), 2.00-2.20 (m, 2H), 2.74 (ddd, J = 6.90, 7.24, 7.59 Hz, 1H), 2.98-3.10 (m, 2H), 3.10-3.32 (m, 2H), 3.39-3.50 (m, 1H),

21

4.44 (dd, J = 4.83, 9.66 Hz, 1H), 4.50-4.60 (m, 1H), 5.48 (dd, J = 4.14, 9.66 Hz, 1H), 7.25-7.50 (m, 5H), 8.10 (d, J = 2.41 Hz, 1H), 8.15 (d, J = 2.41 Hz, 1H); MS (SIMS) m/z 471 (M<sup>+</sup>).

#### 【0065】実施例17

3-フェニルプロピオンニル-N-[1-[(2-チアゾリル)カルボニル]-6-アミノヘキシル]-L-プロリンアミド

3-フェニルプロピオンニル-L-プロリンと2-(2-アミノ-7-(ベンジルオキシカルボニル)アミノ-1-ヒドロキシヘプチル)チアゾールから実施例3と同様な方法で合成した。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.20-1.90 (m, 10H), 1.90-2.08 (m, 1H), 2.08-2.30 (m, 1H), 2.54-2.85 (m, 1H), 2.85-3.06 (m, 6H), 3.25-3.35 (m, 1H), 3.40-3.61 (m, 2H), 4.41 (d, J = 6.90 Hz, 1H), 5.43 (dd, J = 3.45, 8.60 Hz, 1H), 7.14-7.37 (m, 5H), 8.02 (d, J = 24 Hz, 1H), 8.08 (d, J = 24 Hz, 1H); MS (FD) m/z 456 (M<sup>+</sup>).

#### 【0066】実施例18

D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]-4-メトキシベンチル]-L-プロリンアミド

L-プロトキシカルボニル-D-フェニルアラニル-L-プロリンと2-(2-アミノ-1-ヒドロキシ-5-メトキシベンチル)チアゾールから実施例1と同様な方法で合成した。

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.57-1.59 (m, 1H), 1.73-1.88 (m, 5H), 2.07-2.14 (m, 2H), 2.75-2.78 (m, 1H), 3.20-3.33 (m, 2H), 3.35 (s, 3H), 3.49-3.56 (m, 3H), 4.42 (dd, J = 4.2, 8.5 Hz, 1H), 4.53 (m, 1H), 5.49 (dd, J = 4.3, 8.4 Hz, 1H), 7.31-7.34 (m, 2H), 7.41-7.46 (m, 3H), 8.09 (d, J = 3.1 Hz, 1H), 8.14 (d, J = 3.1 Hz, 1H); MS (FD) m/z 459 (M<sup>+</sup>).

#### 【0067】実施例19

D-フェニルアラニル-N-[1-[(2-ベンゾチアゾリル)カルボニル]-4-メトキシベンチル]-L-プロリンアミド

L-プロトキシカルボニル-D-フェニルアラニル-L-プロリンと2-(2-アミノ-1-ヒドロキシ-5-メトキシベンチル)ベンゾチアゾールから実施例1と同様な方法で合成した。

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.74-1.78 (m, 1H), 1.80-1.93 (m, 4H), 2.04-2.19 (m, 2H), 2.73-2.74 (m, 1H), 3.15-3.28 (m, 2H), 3.35 (s, 3H), 3.54-3.58 (m, 4H), 4.40-4.45 (m, 1H), 4.50-4.54 (m, 1H), 5.56 (dd, J = 4.3, 8.4 Hz, 1H), 7.24-7.43 (m, 5H), 7.67-7.73 (m, 2H), 8.15-8.26 (m, 2H); MS (SIMS) m/z = 509 (M<sup>+</sup>).

#### 【0068】実施例20

L-プロトキシカルボニル-D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]-4-メトキシベンチル]-L-プロリンアミド

L-プロトキシカルボニル-D-フェニルアラニル-L-プロリンと2-(2-アミノ-1-ヒドロキシ-5-メトキシベンチル)チア

22

ゾールから合成される実施例18の中間体として得た。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.51-1.90 (m, 14H), 2.15-2.23 (m, 2H), 2.62-2.66 (m, 1H), 3.01-3.04 (m, 2H), 3.30 (s, 3H), 3.38-3.44 (m, 3H), 3.54-3.57 (m, 1H), 4.49-4.62 (m, 2H), 5.40-5.43 (m, 1H), 5.75-5.79 (m, 1H), 7.18-7.32 (m, 5H), 7.53-7.61 (m, 2H), 7.95-7.98 (m, 1H), 8.18-8.21 (m, 1H); MS (FD) m/z 558 (M<sup>+</sup>).

#### 【0069】実施例21

L-プロトキシカルボニル-D-フェニルアラニル-N-[1-[(2-ベンゾチアゾリル)カルボニル]-4-メトキシベンチル]-L-プロリンアミド

L-プロトキシカルボニル-D-フェニルアラニル-L-プロリンと2-(2-アミノ-1-ヒドロキシ-5-メトキシベンチル)ベンゾチアゾールから合成される実施例19の中間体として得た。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.43 (s, 9H), 1.51-1.67 (m, 4H), 1.80-1.89 (m, 2H), 2.07-2.21 (m, 2H), 2.61-2.63 (m, 1H), 2.90-3.05 (m, 2H), 3.30 (s, 3H), 3.33-3.40 (m, 2H), 3.51-3.54 (m, 1H), 4.44-4.48 (m, 1H), 4.62-4.64 (m, 1H), 5.44-5.47 (m, 1H), 5.55-5.62 (m, 1H), 7.20-7.31 (m, 5H), 7.63-7.65 (m, 1H), 7.68 (d, J = 3.0 Hz, 1H), 8.02 (d, J = 3.0 Hz, 1H); MS (FD) m/z 608 (M<sup>+</sup>).

#### 【0070】実施例22

D-フェニルアラニル-N-[1-[(2-チアゾリル)カルボニル]-2-フェニルエチル]-L-プロリンアミド

L-プロトキシカルボニル-D-フェニルアラニル-L-プロリンと2-(2-アミノ-1-ヒドロキシ-3-フェニルプロピル)チアゾールから実施例1と同様な方法で合成した。

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ 1.49-1.54 (m, 2H), 1.60-1.80 (m, 1H), 2.10-2.14 (m, 1H), 2.59-2.67 (m, 1H), 2.85-2.97 (m, 2H), 3.10-3.19 (m, 1H), 3.28-3.49 (m, 2H), 3.64-3.75 (m, 1H), 4.50-4.54 (m, 1H), 5.88-5.93 (m, 1H), 7.20-7.36 (m, 10H), 7.67-7.78 (m, 2H), 8.06-8.08 (m, 1H); MS (SIMS) m/z 477 (M<sup>+</sup>).

#### 【0071】実施例23

4-フェニルブタノイル-N-[1-[(2-チアゾリル)カルボニル]エチル]-L-プロリンアミド

4-フェニルブタノイル-L-プロリンと2-(2-アミノ-1-ヒドロキシプロピル)チアゾールから実施例1と同様な方法で合成した。

<sup>1</sup>H-NMR(D<sub>2</sub>O) δ 1.52 (d, J = 6.90 Hz, 1H), 1.80-2.30 (m, 6H), 2.30-2.38 (m, 2H), 2.68-2.74 (m, 2H), 3.30-3.40 (m, 1H), 3.45-3.52 (m, 1H), 4.62 (dd, J = 2.4, 9.31 Hz, 1H), 5.69 (q, J = 6.90 Hz, 1H), 7.18-7.31 (m, 5H), 7.69 (d, J = 3.10 Hz, 1H), 8.02 (d, J = 3.10 Hz, 1H); MS (FD) m/z 399 (M<sup>+</sup>).

フロントページの続き

(72)発明者 大内 章吉  
神奈川県横浜市港北区師岡町760番地 明  
治製菓株式会社薬品総合研究所内

(72)発明者 初芝 恵実子  
神奈川県横浜市港北区師岡町760番地 明  
治製菓株式会社薬品総合研究所内